<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD006052.pub2" GROUP_ID="NEUROMUSC" ID="849005113018245371" MERGED_FROM="" MODIFIED="2008-04-29 17:50:27 +0200" MODIFIED_BY="Kate Jewitt" REVIEW_NO="085" REVMAN_SUB_VERSION="5.0.4" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="3.0">
<COVER_SHEET MODIFIED="2008-04-29 17:50:27 +0200" MODIFIED_BY="Kate Jewitt">
<TITLE>Treatment for Charcot-Marie-Tooth disease</TITLE>
<CONTACT MODIFIED="2008-04-29 17:50:27 +0200" MODIFIED_BY="Kate Jewitt"><PERSON ID="F7F646CC82E26AA201E74FE94D370BB2" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peter</FIRST_NAME><LAST_NAME>Young</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>young@uni-muenster.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University of Münster </ORGANISATION><ADDRESS_1>Albert-Schweitzer-Str.33</ADDRESS_1><CITY>Münster</CITY><ZIP>48129</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 251 834 8331</PHONE_1><FAX_1>+49 251 8348181</FAX_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2008-04-29 17:50:27 +0200" MODIFIED_BY="Kate Jewitt"><PERSON ID="F7F646CC82E26AA201E74FE94D370BB2" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peter</FIRST_NAME><LAST_NAME>Young</LAST_NAME><POSITION>Professor of Neurology</POSITION><EMAIL_1>young@uni-muenster.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>University of Münster </ORGANISATION><ADDRESS_1>Albert-Schweitzer-Str.33</ADDRESS_1><CITY>Münster</CITY><ZIP>48129</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 251 834 8331</PHONE_1><FAX_1>+49 251 8348181</FAX_1></ADDRESS></PERSON><PERSON ID="F7FEFF7682E26AA201E74FE939306D19" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Peter</FIRST_NAME><LAST_NAME>De Jonghe</LAST_NAME><POSITION>Group Leader</POSITION><EMAIL_1>peter.dejonghe@ua.ac.be</EMAIL_1><URL>www.molgen.ua.ac.be</URL><ADDRESS><DEPARTMENT>VIB - Department of Molecular Genetics, Neurogenetics Group</DEPARTMENT><ORGANISATION>University of Antwerp - CDE</ORGANISATION><ADDRESS_1>Universiteitsplein 1</ADDRESS_1><CITY>Antwerpen</CITY><ZIP>BE-2610</ZIP><COUNTRY CODE="BE">Belgium</COUNTRY><PHONE_1>+32 3 265 1050</PHONE_1><PHONE_2>+32 3 265 1002 sec Gisele Smeyers</PHONE_2><FAX_1>+32 3 265 1012</FAX_1></ADDRESS></PERSON><PERSON ID="F7FAF33582E26AA201E74FE956EDA5FC" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Florian</FIRST_NAME><LAST_NAME>Stögbauer</LAST_NAME><EMAIL_1>florian.stoegbauer@klinikum-os.de</EMAIL_1><ADDRESS><DEPARTMENT>Department of Neurology</DEPARTMENT><ORGANISATION>Klinikum Osnabruck</ORGANISATION><ADDRESS_1>Am Finkenhugel 1</ADDRESS_1><CITY>Osnabruck</CITY><ZIP>49076</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 541 4056500</PHONE_1><FAX_1>+49 541405 6599</FAX_1></ADDRESS></PERSON><PERSON ID="F7F8B4ED82E26AA201E74FE98C1F54C9" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Trude</FIRST_NAME><LAST_NAME>Butterfass-Bahloul</LAST_NAME><EMAIL_1>butterft@mednet.uni-muenster.de</EMAIL_1><ADDRESS><DEPARTMENT>Co-ordinating Centre for Clinical Trials (KKS)</DEPARTMENT><ORGANISATION>University of Münster</ORGANISATION><ADDRESS_1>Von-Esmarch-Str. 62</ADDRESS_1><CITY>Münster</CITY><ZIP>48129</ZIP><COUNTRY CODE="DE">Germany</COUNTRY><PHONE_1>+49 251 8357109</PHONE_1><FAX_1>+49 251 8357026</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2008-04-27 16:35:35 +0100" MODIFIED_BY="Katharine Ker">
<UP_TO_DATE>
<DATE DAY="14" MONTH="11" YEAR="2007"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="14" MONTH="11" YEAR="2007"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="14" MONTH="11" YEAR="2009"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="2" YEAR="2006"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="2008"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2008"/>
</DATES>
<WHATS_NEW>
<WHATS_NEW_ENTRY EVENT="AMENDMENT">
<DATE DAY="27" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="14" MONTH="11" YEAR="2007"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT>
<INTERNAL_SOURCES>
<SOURCE>
<NAME>University of Münster</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION/>
</SOURCE>
<SOURCE>
<NAME>University of Antwerp</NAME>
<COUNTRY CODE="BE">Belgium</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES>
<SOURCE>
<NAME>European Neuromuscular Centre</NAME>
<COUNTRY CODE="NL">Netherlands</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2008-04-27 17:05:33 +0100" MODIFIED_BY="[Empty name]">
<SUMMARY>
<TITLE>Treatment for Charcot-Marie-Tooth disease (hereditary motor and sensory neuropathy)</TITLE>
<SUMMARY_BODY>
<P>Charcot-Marie-Tooth disease is a broad spectrum of different types of inherited peripheral neuropathy. The most common types affect motor and sensory nerves and cause muscle wasting and sensory loss. There have been few trials of treatment for Charcot-Marie Tooth disease. One very small trial of the nerve growth promoting factor, neurotrophin-3, showed possible benefit but needs to be replicated. Trials of exercise, orthosis, creatine and ganglioside injections have been done but did not show significant benefit. These were all too small to identify moderate benefit or harm. Trials of vitamin C for the commonest type of Charcot-Marie Tooth disease are in progress. </P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT>
<ABS_BACKGROUND>
<P>Charcot-Marie-Tooth disease (CMT) comprises a large variety of different forms of motor and sensory neuropathies. The most frequent are demyelinating forms (CMT1) and axonal forms (CMT2). The molecular basis of several CMT forms has been clarified during the last 15 years. Since muscle wasting and sensory disturbance are the main features of these syndromes, treatments aim to improve motor impairment and sensory disturbances. Specific treatment trials are rare.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES>
<P>The objective was to review systematically all randomised and quasi-randomised studies of any treatment for CMT.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY>
<P>We searched the Cochrane Neuromuscular Disease Group Trials Register, MEDLINE (January 1966 to August 2007), EMBASE (January 1980 to August 2007), LILACS (January 1982 to August 2007) for randomised controlled trials of treatment for CMT.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA>
<P>We included randomised and quasi-randomised trials of any treatment for people with CMT. Where a study aimed to evaluate the treatment of general neuromuscular symptoms of people with peripheral neuropathy including CMT, we included the study if we were able to identify the effect of treatment in the CMT group. Observational studies and case reports on the treatment of people with CMT were not included.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION>
<P>Two review authors (PY and TBB) extracted the data, assessed study quality and performed data extraction independently.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS>
<P>Only one trial with only eight participants met all the inclusion criteria and provided the primary outcome measure for this review. In this trial, four participants treated with neurotrophin-3 had more improvement after six months on the Neuropathy Impairment Score, mean difference -9.50 (95% CI -13.77 to -5.23), than those four treated with placebo. Small trials of exercise training, creatine monohydrate, orthoses and purified bovine brain ganglioside injections (Cronassial) showed no significant benefit in people with genetically undefined CMT1 or CMT2. </P>
</ABS_RESULTS>
<ABS_CONCLUSIONS>
<P>Small trials of exercise, creatine, purified brain gangliosides, and orthoses have been performed. None showed significant benefit. A very small trial of neurotrophin-3 showed possible minor benefit which needs to be replicated in a larger trial. None of the two trials were large enough to detect moderate benefit or harm. Larger RCTs are needed for any form of pharmacological intervention as well as as for any form of physical intervention. Outcome measures should include a validated composite scale such as the Charcot-Marie-Tooth neuropathy scale.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2008-04-27 17:05:33 +0100" MODIFIED_BY="[Empty name]">
<BACKGROUND MODIFIED="2008-04-27 16:43:55 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Introduction</HEADING>
<P>Charcot-Marie-Tooth disease (CMT) comprises a huge group of inherited neuropathies which primarily affect either the myelin sheath or the axon of the peripheral nerve (<LINK REF="REF-Dyck-2005a" TYPE="REFERENCE">Dyck 2005a</LINK>). Primary loss of the myelin sheath, called demyelination, leads in most cases to secondary axonal degeneration resulting in muscular atrophy (<LINK REF="REF-Martini-2001" TYPE="REFERENCE">Martini 2001</LINK>). Thus the main motor clinical signs are atrophy and weakness starting in the feet and calves and later affecting the hands (<LINK REF="REF-Dyck-2005a" TYPE="REFERENCE">Dyck 2005a</LINK>). Sensory features are less prominent but may cause much discomfort and add to the disability. Skeletal deformities like scoliosis or foot deformities can be additional features (<LINK REF="REF-Dyck-2005a" TYPE="REFERENCE">Dyck 2005a</LINK>). Depending on the underlying molecular genetic defect the phenotypic features vary from mild weakness to severe paralysis and disability (<LINK REF="REF-Kuhlenbaumer-2002" TYPE="REFERENCE">Kuhlenbaumer 2002</LINK>). Histopathological findings in peripheral nerve biopsies reveal demyelination or axonal degeneration depending on the specific type of CMT. Different patterns of demyelination range from pure demyelination with adequate remyelination to focal demyelinated stretches or pathological folding of the myelin sheath (<LINK REF="REF-Gabreels_x002d_Festen-1993" TYPE="REFERENCE">Gabreels-Festen 1993</LINK>). Demyelination and axonal loss can be differentiated (<LINK REF="REF-Dyck-2005a" TYPE="REFERENCE">Dyck 2005a</LINK>). Demyelination results in severely slowed nerve conduction velocities (NCVs). Types of CMT with primary axonal loss and preserved myelin are characterised by normal or near normal NCVs. Weakness and sensory deficits are the relevant symptoms to be treated and are the focus of this review. Established strategies are lacking for the treatment of CMT and its symptoms (<LINK REF="REF-Young-2001" TYPE="REFERENCE">Young 2001</LINK>). Some trials which aimed to improve muscle strength or sensory deficits have been undertaken. Trials have been performed with corticosteroids and antioxidants, and with physiotherapy for improving muscle function (<LINK REF="REF-Grandis-2005" TYPE="REFERENCE">Grandis 2005</LINK>; <LINK REF="REF-Young-2001" TYPE="REFERENCE">Young 2001</LINK>).</P>
<P>With respect to the genetic basis of CMT syndromes, several animal models have been generated over the last ten years (<LINK REF="REF-Martini-1997" TYPE="REFERENCE">Martini 1997</LINK>; <LINK REF="REF-Young-2001" TYPE="REFERENCE">Young 2001</LINK>). In particular, animal models for the most frequent form of CMT, Charcot-Marie-Tooth type 1A (CMT1A) suggested new approaches to treatment. Vitamin C (Ascorbic acid) (<LINK REF="REF-Passage-2004" TYPE="REFERENCE">Passage 2004</LINK>) and the progesterone antagonist onapristone (<LINK REF="REF-Sereda-2003" TYPE="REFERENCE">Sereda 2003</LINK>) each improved muscle function and reduced demyelination in animal models of CMT1A.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Genetics </HEADING>
<P>A broad spectrum of different gene mutations have been identified as a cause of CMT (<LINK REF="REF-Grandis-2005" TYPE="REFERENCE">Grandis 2005</LINK>; <LINK REF="REF-Pareyson-2004" TYPE="REFERENCE">Pareyson 2004</LINK>; <LINK REF="REF-Young-2001" TYPE="REFERENCE">Young 2001</LINK>). We will give a short introduction of the most frequent forms of CMT, autosomal dominant demyelinating (CMT1), X-chromosome linked Charcot-Marie-Tooth disease (CMTX) and autosomal dominant axonal Charcot-Marie-Tooth disease type 2 (CMT2).<BR/>CMT1 is primarily demyelinating and the most common form of autosomal dominant inherited CMT (<LINK REF="REF-Nelis-1996" TYPE="REFERENCE">Nelis 1996</LINK>). In the last two decades the molecular genetic basis of this syndrome has largely been elucidated (<LINK REF="REF-Young-2003" TYPE="REFERENCE">Young 2003</LINK>).The most frequent genetic defect in CMT1 is an intrachromosomal duplication on chromosome 17p11.2 (<LINK REF="REF-Lupski-1991" TYPE="REFERENCE">Lupski 1991</LINK>; <LINK REF="REF-Nelis-1996" TYPE="REFERENCE">Nelis 1996</LINK>). The gene encoding the peripheral myelin protein 22 (PMP22) is located within the duplicated region (<LINK REF="REF-Timmerman-1992" TYPE="REFERENCE">Timmerman 1992</LINK>). This gene has been shown to be the culprit for the genetic subgroup CMT1A (<LINK REF="REF-Kuhlenbaumer-2002" TYPE="REFERENCE">Kuhlenbaumer 2002</LINK>). CMT1B is defined by the presence of mutations in the gene encoding Myelin Protein Zero (MPZ) (<LINK REF="REF-Hayasaka-1993a" TYPE="REFERENCE">Hayasaka 1993a</LINK>; <LINK REF="REF-Hayasaka-1993b" TYPE="REFERENCE">Hayasaka 1993b</LINK>; <LINK REF="REF-Hayasaka-1993c" TYPE="REFERENCE">Hayasaka 1993c</LINK>). CMT1C is caused by mutation of a gene encoding the LITAF/SIMPLE-protein (LITAF) and was identified recently (<LINK REF="REF-Street-2003" TYPE="REFERENCE">Street 2003</LINK>). The gene encoding the transcription factor early growth arrest protein 2 (EGR2) is responsible for CMT1D (<LINK REF="REF-Young-2003" TYPE="REFERENCE">Young 2003</LINK>).</P>
<P>CMTX is caused by mutations in the gene encoding the gap junction protein beta1 (GJB1) which is localised on the X-chromosome. CMTX is characterised by the histopathological signs of axonal degeneration and demyelination (<LINK REF="REF-Hahn-2001" TYPE="REFERENCE">Hahn 2001</LINK>; <LINK REF="REF-Nicholson-1993" TYPE="REFERENCE">Nicholson 1993</LINK>) which cause the typical electrophysiological features of reduced NCV and reduction of compound muscle action potential as well.</P>
<P>The pure axonal form of CMT is called CMT2 (<LINK REF="REF-Kuhlenbaumer-2002" TYPE="REFERENCE">Kuhlenbaumer 2002</LINK>). Recently mutations in the gene encoding the mitochondrial fusion protein mitofusin 2 were shown to be a frequent cause of CMT2A (<LINK REF="REF-Zuchner-2004" TYPE="REFERENCE">Zuchner 2004</LINK>; <LINK REF="REF-Verhoeven-2006" TYPE="REFERENCE">Verhoeven 2006</LINK>).</P>
<P>Hereditary Neuropathy with Liability to Pressure Palsies (HNPP) represents the only form of CMT which is characterised by recurrent focal nerve palsies without signs of a generalised progressive neuropathy. The underlying genetic defect is the opposite state of CMT1A, namely the loss of one allele of PMP22 due to the loss of the chromosomal fragment on chromosome 17p11.2.</P>
<P>Many more rare dominant and recessive inherited forms of CMT have now been classified (see the Inherited Peripheral Neuropathies Mutations Database http://www.molgen.ua.ac.be/CMTMutations).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Biology</HEADING>
<P>The biological mechanisms which lead to the clinical phenotype are still unclear for many of the responsible genes implicated in specific forms of CMT (<LINK REF="REF-Street-2003" TYPE="REFERENCE">Street 2003</LINK>; <LINK REF="REF-Young-2003" TYPE="REFERENCE">Young 2003</LINK>). For some the biological function has been elucidated with the aid of animal models (<LINK REF="REF-Martini-1997" TYPE="REFERENCE">Martini 1997</LINK>; <LINK REF="REF-Martini-2000" TYPE="REFERENCE">Martini 2000</LINK>) and in vitro experiments (<LINK REF="REF-Suter-2003" TYPE="REFERENCE">Suter 2003</LINK>). In general mutations in CMT disease associated genes lead to disturbed function of either Schwann cells or axons (<LINK REF="REF-Martini-2001" TYPE="REFERENCE">Martini 2001</LINK>). The change in gene dosage in the case of the duplication or the deletion of PMP22 is clear (<LINK REF="REF-Lupski-1992" TYPE="REFERENCE">Lupski 1992</LINK>) but other mutations in CMT associated genes cause the expression of a mutated protein (<LINK REF="REF-Suter-2003" TYPE="REFERENCE">Suter 2003</LINK>). Specific causative gene therapies should regulate the expression of a mutated protein either at the DNA or RNA level (<LINK REF="REF-Young-2001" TYPE="REFERENCE">Young 2001</LINK>). In the diseases with different mutations within the same gene, one would have to establish gene therapy strategies for each individual mutation. For CMT1A, in which alteration of the gene dosage of PMP22 is the underlying mechanism, therapeutic approaches will need to aim at regulating the amount of expressed PMP22 protein. After an initial phase of correct myelination during development, overexpression or underexpression of PMP22 in the myelinating Schwann cell causes dysmyelination or demyelination, as was shown in a PMP22 deficient mouse model (<LINK REF="REF-Adlkofer-1995" TYPE="REFERENCE">Adlkofer 1995</LINK>; <LINK REF="REF-Adlkofer-1997" TYPE="REFERENCE">Adlkofer 1997</LINK>). Further PMP22 protein dosage alterations cause incorrect incorporation of myelin proteins into the myelin membranes (<LINK REF="REF-Suter-2003" TYPE="REFERENCE">Suter 2003</LINK>).</P>
<P>In the CMT1B and CMTX subgroups, mouse models showed that the demyelinating phenotype was associated with an immune response (<LINK REF="REF-Maurer-2002" TYPE="REFERENCE">Maurer 2002</LINK>). Reducing this immune response reduced the degree of demyelination and in parallel the behavioural deficits in these animals. This observation raised the question whether modulation of the immune system could be a helpful therapeutic strategy for CMT1B and CMTX.</P>
<P>CMT disease is commonly due to genes encoding structural proteins. It may also be due to other genes such as those encoding transcription factors, or enzymes or genes associated with mitochondria (<LINK REF="REF-Grandis-2005" TYPE="REFERENCE">Grandis 2005</LINK>). The biological function of many of these genes is still unknown. The variety of the involved genes emphasises the fact that myelination, myelin maintenance and axonal integrity are the product of complex interactions of many proteins besides structural ones (<LINK REF="REF-Martini-2001" TYPE="REFERENCE">Martini 2001</LINK>). These interactions, if understood in more detail, will become the focus of future therapeutic approaches.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Clinical features</HEADING>
<P>Although molecular genetic methods for the identification of new genes in CMT have been developed quickly, CMT1A remains the most common (<LINK REF="REF-Nelis-1996" TYPE="REFERENCE">Nelis 1996</LINK>). The most prominent symptom in all forms of CMT1 is progressive distal wasting of peroneal muscles resulting in distal weakness beginning in the second decade (<LINK REF="REF-Kuhlenbaumer-2002" TYPE="REFERENCE">Kuhlenbaumer 2002</LINK>). Many people with CMT1 have foot deformities. Sensory symptoms include tingling, burning or aching of feet and legs. Autonomic nervous system involvement is rare and not prominent. Erectile dysfunction may occur due to progressive involvement of the relevant motor and sensory nerves (<LINK REF="REF-Dyck-2005a" TYPE="REFERENCE">Dyck 2005a</LINK>). Need for a wheelchair is rare. People carrying point mutations in the PMP22 gene may be more severely affected (<LINK REF="REF-Young-2001" TYPE="REFERENCE">Young 2001</LINK>).</P>
<P>The pathobiological hallmarks of CMT1 are demyelination and axonal degeneration with consequent muscle atrophy (<LINK REF="REF-Krajewski-1999" TYPE="REFERENCE">Krajewski 1999</LINK>; <LINK REF="REF-Krajewski-2000" TYPE="REFERENCE">Krajewski 2000</LINK>). With the aid of motor nerve conduction velocity (MNCV) measurements demyelination can be identified by reduction of motor NCV. Reduction in NCV does not reflect the clinical severity of CMT1 (<LINK REF="REF-Krajewski-1999" TYPE="REFERENCE">Krajewski 1999</LINK>; <LINK REF="REF-Krajewski-2000" TYPE="REFERENCE">Krajewski 2000</LINK>). For the diagnosis of CMT1 a reduced MNCV of less than 38 m/sec in the ulnar nerve is required (<LINK REF="REF-Dyck-2005a" TYPE="REFERENCE">Dyck 2005a</LINK>). Axonal CMT2 cannot be differentiated by clinical means from CMT1 but the MNCV is normal or only slightly reduced in CMT2 although the compound motor action amplitudes (CMAP) are significantly decreased (<LINK REF="REF-Dyck-2005a" TYPE="REFERENCE">Dyck 2005a</LINK>; <LINK REF="REF-Harding-1980" TYPE="REFERENCE">Harding 1980</LINK>).</P>
</SUBSECTION>
</BACKGROUND>
<OBJECTIVES>
<P>The objective was to review systematically all randomised and quasi-randomised studies of any treatment for CMT.</P>
</OBJECTIVES>
<METHODS>
<SELECTION_CRITERIA>
<CRIT_STUDIES>
<P>We included randomised and quasi-randomised trials of any treatment for people with CMT. Where a study aimed to evaluate the treatment of general neuromuscular symptoms of people with peripheral neuropathy including CMT we included the study if we were able to identify the effect of treatment in the CMT group. Observational studies and case reports on the treatment of patients with CMT were not included.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS>
<P>Because of the heterogeneity of CMT we included people with all types of CMT regardless of whether clinical, electrophysiological, histopathological or molecular genetic criteria were used. Due to the fast progress in the elucidation of the genetic basis of CMT, we considered rare forms of CMT. Experimental data from animal models were not included.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS>
<P>We included all drug and physical treatments. Drugs were likely to include corticosteroids, antioxidants such as Vitamin E, lipoic acid and coenzyme Q. With regard to future developments, studies using molecular approaches like RNA interference (RNAi) with the aid of small interfering RNAs (siRNAs), antisense or ribozymes were included when available. Physical treatments included exercise and different physiotherapy strategies. Treatment should extend for at least 12 successive weeks. Twelve weeks of treatment was chosen as a minimum because the very slow progressive course of CMT makes it seem unlikely to us that a shorter period of treatment would be an adequate test of its efficacy.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2008-04-27 16:45:04 +0100" MODIFIED_BY="[Empty name]">
<P>Changes and numbers of events occurring, over time were re-scaled to `change or number of events in a fixed period`, for example three months, to permit the pooling of studies with differing follow-up periods.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2008-04-27 16:45:08 +0100" MODIFIED_BY="[Empty name]">
<P>Change in impairment after at least 12 weeks.<BR/>We accepted any measure of impairment made with a validated scale, such as the MRC sum score, Neuropathy Impairment Score (NIS) (<LINK REF="REF-Dyck-2005b" TYPE="REFERENCE">Dyck 2005b</LINK>), Total Neuropathy Score (<LINK REF="REF-Cornblath-1999" TYPE="REFERENCE">Cornblath 1999</LINK>), or CMT Neuropathy score (<LINK REF="REF-Shy-2005" TYPE="REFERENCE">Shy 2005</LINK>). The last two are composite scores of different aspects of impairment.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2008-04-27 16:48:26 +0100" MODIFIED_BY="[Empty name]">
<P>Secondary outcome measures included:</P>
<OL>
<LI>Change in disability after at least 12 weeks. We accepted any measure of disability made with a validated scale such as the Rankin Scale (<LINK REF="REF-van-Swieten-1988" TYPE="REFERENCE">van Swieten 1988</LINK>) or the Inflammatory Neuropathy Cause and Treatment Overall Disability Status Scale (<LINK REF="REF-Merkies-2000" TYPE="REFERENCE">Merkies 2000</LINK>).</LI>
<LI>Change of maximum compound muscle action potential amplitudes (CMAP) of the ulnar median or peroneal nerve one year after randomisation because it has been shown that disability is best correlated to CMAP measures (<LINK REF="REF-Krajewski-1999" TYPE="REFERENCE">Krajewski 1999</LINK>; <LINK REF="REF-Krajewski-2000" TYPE="REFERENCE">Krajewski 2000</LINK>).</LI>
<LI>Change in sensory impairment one year after randomisation measured with a validated scale.</LI>
<LI>Change in sensory nerve action potential amplitude (SNAP) of the sural or other sensory nerves.</LI>
<LI>Change of grip force as measured with the aid of dynamometer or vigorimeter after one year of randomisation.</LI>
<LI>Quality of life assessment using validated scores as SF-36 health related quality of life scale (<LINK REF="REF-Jenkinson-1993" TYPE="REFERENCE">Jenkinson 1993</LINK>) or EuroQol (<LINK REF="REF-Anderson-1996" TYPE="REFERENCE">Anderson 1996</LINK>) one year following randomisation.</LI>
<LI>Adverse events, whether minor or severe, caused by any form of treatment. We distinguished between minor adverse events and severe adverse events (those which were fatal, life-threatening, required or prolonged hospitalisation or caused discontinuation of the treatment).</LI>
</OL>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2008-04-27 16:49:14 +0100" MODIFIED_BY="[Empty name]">
<ELECTRONIC_SEARCHES MODIFIED="2008-04-27 17:05:33 +0100" MODIFIED_BY="[Empty name]">
<P>We searched the Cochrane Neuromuscular Disease Group Trials Register, MEDLINE (January 1966 to August 2007), EMBASE (January 1980 to August 2007), LILACS (January 1982 to August 2007) for randomised controlled trials using 'Charcot-Marie-Tooth disease' and its synonyms 'hereditary motor and sensory neuropathy', 'inherited neuropathy', 'peroneal muscular atrophy' and 'distal spinal muscular atrophy' as the search terms. For MEDLINE, EMBASE and LILACS search terms see <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>, <LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK> and <LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK> respectively.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2008-04-27 16:49:08 +0100" MODIFIED_BY="[Empty name]">
<P>Authors from clinical trials and experts from the field were contacted to identify unpublished trials. We also checked the bibliographies of trials identified.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2008-04-27 16:51:51 +0100" MODIFIED_BY="[Empty name]">
<STUDY_SELECTION MODIFIED="2008-04-27 16:51:34 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors checked the titles and abstracts of the articles identified by the search.</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2008-04-27 16:51:26 +0100" MODIFIED_BY="[Empty name]">
<P>Data were extracted independently by at least two review authors onto a specially designed data extraction form. We contacted trial authors to obtain missing data or raw data if necessary.</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2008-04-27 16:51:07 +0100" MODIFIED_BY="[Empty name]">
<P>Two review authors (TBB and PY) decided which trials fitted the inclusion criteria and graded the methodological quality using the Cochrane approach: A: adequate, B: unclear, C: inadequate or not done. The methodological quality assessment took into account security of randomisation, allocation concealment, patient blinding, observer blinding, explicit inclusion criteria, extent to which the study took into account any imbalance in prognostic important variables present at time of randomisation, and completeness of follow-up.</P>
</QUALITY_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2008-04-27 16:52:28 +0100" MODIFIED_BY="[Empty name]">
<P>If data were available for more than one trial with a specific intervention, we used the Cochrane Review Manager 4.2 (RevMan) software to pool data. We summarised continuous data with weighted mean differences (WMD) and 95% confidence intervals (CIs). In case we found outcomes measured with different scales, standardised mean differences (SMD) were used. Dichotomised data were analysed with relative risks with 95% CIs. </P>
<P>In the 'Discussion' we considered adverse events and cost-effectiveness taking into account information from the non-randomised literature.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2008-04-27 16:52:34 +0100" MODIFIED_BY="[Empty name]">
<P>If heterogeneity was found we explored and described possible reasons for differences between studies such as types of participants, intervention or quality.</P>
<P>We separately compared CMT1, CMT2 and where possible other CMT subgroups. Due to the fact that CMT1A was the most frequent form of CMT, we considered CMT1A separately whenever possible.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2008-04-27 16:50:52 +0100" MODIFIED_BY="[Empty name]">
<P>We performed sensitivity analyses by omitting trials which lacked one or more of the methodological attributes. If necessary we used the random-effects model to obtain the pooled estimates.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS>
<STUDY_DESCRIPTION MODIFIED="2008-04-27 16:54:10 +0100" MODIFIED_BY="[Empty name]">
<P>We finally identified 41 references including 38 different studies describing treatment of any form of CMT but only six of them were randomised studies. As in two other systematic reviews dealing with exercise for people with peripheral neuropathies (<LINK REF="REF-White-2004" TYPE="REFERENCE">White 2004</LINK>) and with strength training and aerobic exercise training for muscle disease (<LINK REF="REF-van-der-Kooi-2005" TYPE="REFERENCE">van der Kooi 2005</LINK>), we identified three articles dealing with the same randomised controlled study group (<LINK REF="STD-Lindemann-1994" TYPE="STUDY">Lindemann 1994</LINK>; <LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>; <LINK REF="STD-Lindeman-1999" TYPE="STUDY">Lindeman 1999</LINK>). In the following we only refer to the article from Lindeman 1995. In total we only included six small studies whose details are given in the Table 'Characteristics of included studies'. The interventions were exercise (<LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>), oral creatine monohydrate (<LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>; <LINK REF="STD-Chetlin-2004" TYPE="STUDY">Chetlin 2004</LINK>), parenteral Neurotrophin-3 (NT-3) (<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>), subcutaneous preparation of purified bovine gangliosides (Cronassial) (<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>) and foot orthoses (<LINK REF="STD-Burns-2006" TYPE="STUDY">Burns 2006</LINK>).</P>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2008-04-27 16:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>The methodological quality scores of the included studies as assessed by the review authors are given in Additional <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK> 'Methodological quality'.<BR/>
<I>
<BR/>
</I>The study analysing strength training in CMT participants (<LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>) was individually matched in relation to muscle strength and timed stair climbing. Detailed description of the method of randomisation and allocation concealment were not given in the paper but the first author of the study gave information on request. Randomisation and allocation were done in calculating comparable z-scores for each participant after having calculated peak/body weight ratios (mean knee extension torques divided by body weight) and performance on a stair climbing test (seconds). A statistician made a computer program to calculate all possible combinations of 15 pairs, looking for the optimal mix. Matching was done by two independent people who drew a sealed lot per matched pair and allocated it by tossing a coin to the training or non-training group. Explicit diagnostic criteria for specific CMT subforms were not given but differentiation of CMT1 and CMT2 was claimed in accordance to clinical and electrophysiological data.<BR/>
<BR/>For the main article about the study testing the combination of resistance training and creatine monohydrate (<LINK REF="STD-Chetlin-2004" TYPE="STUDY">Chetlin 2004</LINK>), explicit methods of randomisation and expicit inclusion criteria were not given. However, another article about the same participants described randomisation (<LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>). One of the coauthors of this study (S. Alway) provided comprehensive information. Randomisation was done by using block randomisation to assign participants to their respective groups (creatine or placebo). Numerical block positions were designated 1 to 8, 9 to 16, and 17 to 20. Twenty paper squares, 10 for each of the two groups, were evenly apportioned and drawn from a container sight unseen. Once drawn, each paper square was discarded in order to assure an equal number of group designations for each block. CMT diagnosis was done on a clinical, electrophysiological and genetic basis without recording the exact genotypes included in the study.</P>
<P>In the study analysing the effect of creatine monohydrate without physical training, genetic testing was also done (<LINK REF="STD-Doherty-2001" TYPE="STUDY">Doherty 2001</LINK>). The method of randomisation was not given. Unfortunately detailed information was not made available.</P>
<P>In 1988 genetic testing was not available for CMT syndromes and inclusion criteria for the study using Cronassial were based on clinical and electrophysiological data (<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>). In this study individuals suffering from other neuropathy causing diseases (e.g. diabetes) were excluded (<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>). From these data CMT participants were subdivided in CMT1 and CMT2. In the study analysing the impact of NT-3 in CMT1A participants (<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>), the method of randomisation was given in detail. The presence of the duplication on choromosome 17p11.2 was an explicit inclusion criterion.</P>
<P>None of the randomised studies defined a minimum level of impairment or disability at baseline.<BR/>
<BR/>All studies explicitly recorded the number and reasons for drop outs in the different experimental groups. For statistical assessment drop outs were claimed to be considered.</P>
<P>Blinding of the observer as of the participant was reported in all studies in which medication was tested (<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>; <LINK REF="STD-Chetlin-2004" TYPE="STUDY">Chetlin 2004</LINK>; <LINK REF="STD-Doherty-2001" TYPE="STUDY">Doherty 2001</LINK>; <LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>). Side effects at the injection sites which were reported in the Cronassial (<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>) studies and in the NT-3 study (<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>) were not reported to be causes for unblinding of the participants. Due to the nature of physical exercise, patient blinding was not possible in the study on strength training (<LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>).</P>
<P>None of the studies considered explicitly differences in baseline characteristics. Age of onset and duration of the disease were not given in any of the studies. Two studies used impairment scores to compare groups. The NIS was used in one (<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>) and an undefined score in the other (<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>). The studies of physical training (<LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>), physical training in combination with creatine monohydrate (<LINK REF="STD-Chetlin-2004" TYPE="STUDY">Chetlin 2004</LINK>; <LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>) or impact of foot orthoses did not use validated scores to measure impairment. The trial analysing the effect of orthoses concerning pain used an unspecified quality of life questionaire (<LINK REF="STD-Burns-2006" TYPE="STUDY">Burns 2006</LINK>).</P>
<P>Recordings of the completeness of the trials were given in all studies. Drop outs were reported in three studies (<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>; <LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>; <LINK REF="STD-Chetlin-2004" TYPE="STUDY">Chetlin 2004</LINK>). In the trial by <LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>, the matched pairs design demanded removal of one matched control participant.</P>
<P>All studies described interventions and the related procedures in detail. Two trials using physical training as an interventional parameter gave detailed information about duration, intensity and setting of the therapy (<LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>; <LINK REF="STD-Chetlin-2004" TYPE="STUDY">Chetlin 2004</LINK>). Doses of medication, duration of intake and mode of application were also recorded in detail in the studies analysing pharmacological intervention in CMT (<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>; <LINK REF="STD-Doherty-2001" TYPE="STUDY">Doherty 2001</LINK>; <LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>; <LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>). In the study using orthoses, detailed information on the treatment and placebo were given (<LINK REF="STD-Burns-2006" TYPE="STUDY">Burns 2006</LINK>)</P>
<P>Definition and description of outcome criteria were given in all studies we selected. Because only one study used an impairment score as a primary outcome measure (<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>), the review authors decided to include all randomised studies in which defined outcome measures were reported. Furthermore in one trial the observation period was shorter than the minimum of 12 weeks (<LINK REF="STD-Doherty-2001" TYPE="STUDY">Doherty 2001</LINK>) which we defined as a prerequisite for inclusion. Due to the clear definition of the outcome measure this trial was included. Quality of life was assessed in one study. However, defined and validated questionaires were not used for quality of life assessement (<LINK REF="STD-Burns-2006" TYPE="STUDY">Burns 2006</LINK>). In the trial in which muscle fibre size (<LINK REF="STD-Chetlin-2004" TYPE="STUDY">Chetlin 2004</LINK>) and biochemically proven amount of myosin heavy chain composition (<LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>) were analysed as an outcome measure, techniques to assemble the data were described in detail as in the study of Neurotrophin-3 (<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>) in CMT1A, too.</P>
<P>None of the selected studies had top scores on all items using the Cochrane approach. Without the unpublished data, even quality assessment of the randomisation items would have been unclear in three trials. Scoring for each of the included studies, done independently by two of the review authors (PY and TBB) are shown in <LINK REF="TBL-01" TYPE="TABLE">Table 1</LINK>. Their scores coincided for all included trials.</P>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2008-04-27 17:04:25 +0100" MODIFIED_BY="[Empty name]">
<P>Due to the heterogeneity of the different studies and the great variability of presentation of the data, pooling of data was not possible. The results are given for each intervention separately in relation to the predefined outcome measures.</P>
<SUBSECTION>
<HEADING LEVEL="3">Neurotrophin-3 </HEADING>
<P>(<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>)<B>
<BR/>
</B>One NT-3 study was identified in which impairment was measured with the use of a composite scale. In this parallel group double blind study (<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>) with eight participants, four receiving NT-3 and four receiving placebo, the NIS scale was used at baseline and after 24 weeks of treatment. Subscoring was performed with respect to motor, sensory and reflex status of the participants, which were people with genetically proven CMT1A. Mean differences between the treatment group and the placebo group were -9.50 (95% Cl -13.77 to -5.23) (see Analysis 01.01) in the overall NIS. Subscoring for motor items showed a mean difference of -0.50 (95% CI -2.42 to 1.42) (see Analysis 01.02). Mean difference for sensory scores was -4.80 (95% CI -8.08 to -1.52) (see Analysis 01.03), and mean difference for reflex score was -4.50 (95% CI -7.65 to -1.35) (see Analysis 01.04). These data indicate a significant but slight improvement of sensory and reflex scores but not of motor function.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Exercise </HEADING>
<P>(<LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>)<BR/>Grip force as indicating change in muscle strength was not measured with the aid of dynamometer or vigorimeter in any of the studies. However muscle strength was measured in one study in people suffering from neuropathies (<LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>; <LINK REF="STD-Lindeman-1994b" TYPE="STUDY">Lindeman 1994b</LINK>). This study showed a significant reduction in time needed for six metre comfortable walking at 24 weeks after starting the exercise with a WMD of 0.70 (95% CI 0.23 to 1.17) (see Analysis 02.04). This study also reported significant improvement of isokinetic knee extension torque in the exercise group at 24 weeks after starting with a WMD of 17.70 (95% CI 5.11 to 30.29) (see Analysis 02.01). Isokinetic knee flexion torque was not improved, WMD 6.10 (95% CI 0.29 to 11.91) (see Analysis 02.02). Maximal isometric voluntary contraction force was also not significantly improved in the exercise group, WMD 12.60 (95% CI -1.51 to 26.71) (see Analysis 02.03).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Foot orthoses</HEADING>
<P>(<LINK REF="STD-Burns-2006" TYPE="STUDY">Burns 2006</LINK>)<BR/>Pain was measured in one study analysing the benefit of foot orthoses in a subset of CMT participants. The use of foot orthoses did not significantly improve functional outcome in nine CMT participants compared with seven given sham insoles (Burns 2006), MD 6.00 (CI -15.25 to 27.25) (see Analysis 03.02). Pain was also not significantly improved in the orthoses group, WMD 12.90 (95% CI -21.09 to 46.89) (see Analysis 03.01).<BR/>Quality of life was assessed in this study using the SF36 Health Survey with the items physical functioning WMD of 4.80 (95% CI -12.09 to 21.69) (see Analysis 03.03), general health WMD of 1.90 (95% CI -19.57 to 23.37) (see Analysis 03.04), vitality WMD of 10.20 (95% CI -2.69 to 23.09) (see Analysis 03.05) and social functioning WD of -1.50 (95% CI -19.18 to 16.18) (see Analysis 03.06).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Subcutaneous bovine brian gangliosides injections </HEADING>
<P>(<LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>)<BR/>In this trial none of the predefined outcome measures were reported.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Oral Creatine monohydrate </HEADING>
<P>(<LINK REF="STD-Chetlin-2004" TYPE="STUDY">Chetlin 2004</LINK>; <LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>)</P>
<P>In this trial none of the predefined outcome measures were reported.
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events, whether minor or severe, caused by any form of treatment</HEADING>
<P>We distinguished between minor and severe adverse events (those which were fatal, life-threatening, required or prolonged hospitalisation or caused discontinuation of the treatment). The adverse events from included and excluded studies are given in Additional <LINK REF="TBL-02" TYPE="TABLE">Table 2</LINK> 'Adverse events for interventions with drugs or food supplements<I>'</I> and in Additional <LINK REF="TBL-03" TYPE="TABLE">Table 3</LINK> 'Adverse events for non-drug, non surgical interventions'<I>. </I>Further information is also given in the 'Characteristics of excluded studies' Table<I>.</I>
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">Adverse events for surgical interventions</HEADING>
<P>Interventions on the lower extremities found in the literature were triple arthrodesis (<LINK REF="STD-Mann-1992" TYPE="STUDY">Mann 1992</LINK>; <LINK REF="STD-Saltzman-1999" TYPE="STUDY">Saltzman 1999</LINK>; <LINK REF="STD-Wetmore-1989" TYPE="STUDY">Wetmore 1989</LINK>), posterior tibial tendon transfers (<LINK REF="STD-Miller-1982" TYPE="STUDY">Miller 1982</LINK>), various surgical interventions (<LINK REF="STD-Brown-1992" TYPE="STUDY">Brown 1992</LINK>), use of a hinged distraction apparatus (<LINK REF="STD-Oganesyan-1996" TYPE="STUDY">Oganesyan 1996</LINK>), and periacetabular osteotomy (<LINK REF="STD-Trumble-1999" TYPE="STUDY">Trumble 1999</LINK>). Interventions on the upper extremities comprised tendon transfers of upper limb (<LINK REF="STD-Wood-1995" TYPE="STUDY">Wood 1995</LINK>) and extensor pollicis longus-opponensplasty (<LINK REF="STD-Riley-1980" TYPE="STUDY">Riley 1980</LINK>). Additionally there was an article about microvascular decompression for trigeminal neuralgia in three CMT patients (<LINK REF="STD-de-Matas-2000" TYPE="STUDY">de Matas 2000</LINK>). In summary adverse events were non-specific and were not peculiar to the CMT phenotype.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2008-04-27 16:58:29 +0100" MODIFIED_BY="[Empty name]">
<SUBSECTION>
<HEADING LEVEL="2">Included studies, number of participants in total</HEADING>
<P>In total we identified six different trials describing the medical or physical treatment of CMT syndromes in a randomised controlled study design. Only one study fulfilled a subset of the inclusion criteria defined in the protocol. In this study in total eight people with genetically proven CMT1A were included (<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>). It was the only study to be judged as adequate. None of the other included studies met the predefined inclusion criteria. However two more studies were analysed due to their study design fulfilling the criteria to be a randomised clinical trial with regard to the Cochrane approach (<LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>; <LINK REF="STD-Burns-2006" TYPE="STUDY">Burns 2006</LINK>). These two trials were small and did not focus on CMT but CMT turned out to be a subgroup in these studies. Three other trials did not report the outcome measures selected for this review (<LINK REF="STD-Smith-2006" TYPE="STUDY">Smith 2006</LINK>; <LINK REF="STD-Doherty-2001" TYPE="STUDY">Doherty 2001</LINK>; <LINK REF="STD-Bradley-1988" TYPE="STUDY">Bradley 1988</LINK>).</P>
<P>The NT-3 study and the study testing the use of foot orthoses were the only studies in which people with genetically proven CMT1A were included. In all other studies, CMT1 and CMT2 were diagnosed by clinical and electrophysiological aspects. How far participants who were included in these studies were comparable is unclear since data on severity evaluated in a composite scale (<LINK REF="REF-Shy-2005" TYPE="REFERENCE">Shy 2005</LINK>) were not given in any of these studies.</P>
<P>In the studies in which the muscle fibre diameter was analysed following a defined orally administered dosage of creatine monohydrate in combination with defined physical exercise (<LINK REF="STD-Chetlin-2004" TYPE="STUDY">Chetlin 2004</LINK>), no change on outcome parameters was reported, but detailed data were not given. The amount of myosin heavy chain composition was not changed in the placebo group nor in the group receiving creatine monohydrate in combination with strength exercise (<LINK REF="STD-Doherty-2001" TYPE="STUDY">Doherty 2001</LINK>). The administration of creatine alone in CMT1 and 2 did not show any effect on the amount of myosin heavy chain (<LINK REF="STD-Doherty-2001" TYPE="STUDY">Doherty 2001</LINK>).</P>
<P>Only one study focused on people with CMT1 but the number of participants included was very small (<LINK REF="STD-Sahenk-2005" TYPE="STUDY">Sahenk 2005</LINK>). People with CMT represented subgroups in all other studies which were designed for people with different kinds of neuromuscular diseases.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Quality of study design</HEADING>
<P>The studies which were identified as RCTs used appropriate randomisation methods.</P>
<P>Blinding was done in all studies except studies in which physical exercise was evaluated (<LINK REF="STD-Lindeman-1995" TYPE="STUDY">Lindeman 1995</LINK>) and blinding was not possible. Numbers of CMT participants were low in all studies and statistical power analysis was not given.
</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Types of interventions</HEADING>
<P>None of the trials had significantly long follow-up to detect differences in rate of progression of CMT between treatment groups (<LINK REF="REF-Reilly-2006" TYPE="REFERENCE">Reilly 2006</LINK>). Furthermore two outcome measures, and especially the CMT-neuropathy score, now favoured for CMT trials (<LINK REF="REF-Reilly-2006" TYPE="REFERENCE">Reilly 2006</LINK>) were not used.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="2">Limitation of the review</HEADING>
<P>The small number of trials which fulfilled the selection criteria for this review reflects the difficulties of undertaking clinical trials in CMT. This review demonstrates the lack of adequate RCTs in CMT.</P>
<P>Since CMT is biologically and genetically heterogeneous and shows great variability in severity, we had wanted to analyse different subgroups but the lack of data made this impossible. In updates of this review we intend to consider CMT1 and CMT2 separately. The selection of outcome measures was specified for CMT taking in account the slow natural history of CMT1 and CMT2. Thus study quality was low in all selected studies with regard to this selection criterion.</P>
<P>The lack of availability of genetic testing in these old studies limited the definition of different CMT syndromes. In future CMT1 and CMT2 will be of the most clinical importance (<LINK REF="REF-Nelis-1996" TYPE="REFERENCE">Nelis 1996</LINK>; <LINK REF="REF-Young-2003" TYPE="REFERENCE">Young 2003</LINK>; <LINK REF="REF-Verhoeven-2006" TYPE="REFERENCE">Verhoeven 2006</LINK>).</P>
<P>Since in a mouse model of CMT1A, vitamin C was shown to be effective in improving motor function as well as to enhance remeylination (<LINK REF="REF-Passage-2004" TYPE="REFERENCE">Passage 2004</LINK>) several vitamin C studies were initiated within the last two years (see Ongoing trials). Most of these trials are conducted in accordance to expert recommendations (<LINK REF="REF-Reilly-2006" TYPE="REFERENCE">Reilly 2006</LINK>) and will offer the first set of data from treating CMT1A in multicentre trials (<LINK REF="REF-Pareyson-2006" TYPE="REFERENCE">Pareyson 2006</LINK>). Data from these trials will be included in review when available.</P>
</SUBSECTION>
</DISCUSSION>
<CONCLUSIONS>
<IMPLICATIONS_PRACTICE>
<P>For clinical practice none of the studies showed significant benefit from the interventions tested for any CMT syndrome. Possible benefit from NT-3 was shown in a very small trial. However the use of NT-3 may be promising but is at this point far from being applicable in clinical routine. None of the trials was large enough to identify or exclude even moderate benefit or harm.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH>
<P>There is a need for properly designed trials of interventions in CMT. Such trials should have adequate follow-up, use appropriate outcome measures such as the validated CMT-NS composite outcome measure, and be powered to detect a clinically important result. The results of trials such as vitamin C are awaited.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS>
<P>The authors wish to thank Professor Richard Hughes and Janice Fernandes for critical reading of the review. Kate Jewitt's continuous help not just to understand the differences between RefMan and RevMan but to use the last one as well is very much appreciated.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST>
<P>None</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS>
<P>Peter Young wrote the first and all subsequent drafts. Florian Stögbauer and Peter De Jonghe commented on the first and subsequent drafts. Trude Butterfass-Bahloul commented on subsequent drafts and supported the systematic search for literature, the review of the literature and systematic biometric analysis. All four authors agreed the final text.</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF/>
<PUBLIC_NOTES/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES>
<STUDIES>
<INCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Bradley-1988" NAME="Bradley 1988" YEAR="1988">
<REFERENCE NOTES="&lt;p&gt;Department of Neurology, University of Vermont, BurlingtonFAU - Bradley, W G&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bradley WG, Badger GJ, Tandan R, Fillyaw MJ, Young J, Fries TJ, et al</AU>
<TI>Double-blind controlled trials of Cronassial in chronic neuromuscular diseases and ataxia</TI>
<SO>Neurology</SO>
<YR>1988</YR>
<VL>38</VL>
<NO>11</NO>
<PG>1731-1739</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1849"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Burns-2006" NAME="Burns 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;DA - 20060518&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Burns J, Crosbie J, Ouvrier R, Hunt A</AU>
<TI>Effective orthotic therapy for the painful cavus foot: a randomized controlled trial</TI>
<SO>Journal of the American Podiatric Medical Association</SO>
<YR>2006</YR>
<VL>96</VL>
<NO>3</NO>
<PG>205-211</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Chetlin-2004" NAME="Chetlin 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Department of Human Performance and Applied Exercise Science, West Virginia University, PO Box 9139, Morgantown, West Virginia 26506-9139, USA rchetlin@hscwvueduFAU - Chetlin, Robert D&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chetlin RD, Gutmann L, Tarnopolsky MA, Ullrich IH, Yeater RA</AU>
<TI>Resistance training exercise and creatine in patients with Charcot-Marie-Tooth disease</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2004</YR>
<VL>30</VL>
<NO>1</NO>
<PG>69-76</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="336"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Doherty-2001" NAME="Doherty 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Department of Physical Medicine and Rehabilitation and Lawson Health Research Institute, University of Western Ontario, London, Canada timdoherty@lhsconcaFAU - Doherty, T J&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Doherty TJ, Lougheed K, Markez J, Tarnopolsky MA</AU>
<TI>Creatine monohydrate does not increase strength in patients with hereditary neuropathy</TI>
<SO>Neurology</SO>
<YR>2001</YR>
<VL>57</VL>
<NO>3</NO>
<PG>559-60</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="728"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lindeman-1995" NAME="Lindeman 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Department of Rehabilitation, University Hospital Maastricht, The NetherlandsFAU - Lindeman, E&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindeman E, Leffers P, Spaans F, Drukker J, Reulen J, Kerckhoffs M, et al</AU>
<TI>Strength training in patients with myotonic dystrophy and hereditary motor and sensory neuropathy: a randomized clinical trial</TI>
<SO>Archives of Physical and Medical Rehabilitation</SO>
<YR>1995</YR>
<VL>76</VL>
<NO>7</NO>
<PG>612-20</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="2102"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lindeman-1999" NAME="Lindeman 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Department of Rehabilitation, University Hospital Maastricht, The Netherlands elindeman@pmbrazunlFAU - Lindeman, E&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindeman E, Spaans F, Reulen J, Leffers P, Drukker J</AU>
<TI>Progressive resistance training in neuromuscular patients. Effects on force and surface EMG</TI>
<SO>Journal of Electromyography and Kinesiology</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>6</NO>
<PG>379-84</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="913"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindemann-1994" NAME="Lindemann 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindeman E, Drukker J</AU>
<TI>Specificity of strength training in neuromuscular disorders</TI>
<SO>Journal of Rehabilitation Sciences</SO>
<YR>1994</YR>
<VL>7</VL>
<NO>Suppl.</NO>
<PG>13-15</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Sahenk-2005" NAME="Sahenk 2005" YEAR="2005">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Sahenk Z, Nagaraja HN, McCracken BS, King WM, Freimer ML, Cedarbaum JM, et al</AU>
<TI>NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>65</VL>
<NO>5</NO>
<PG>681-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Smith-2006" NAME="Smith 2006" YEAR="2006">
<REFERENCE NOTES="&lt;p&gt;DA - 20060801&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Smith CA, Chetlin RD, Gutmann L, Yeater RA, Alway SE</AU>
<TI>Effects of exercise and creatine on myosin heavy chain isoform composition in patients with Charcot-Marie-Tooth disease</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2006</YR>
<VL>34</VL>
<NO>5</NO>
<PG>586-94</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES>
<STUDY DATA_SOURCE="PUB" ID="STD-Aras-2005" NAME="Aras 2005" YEAR="2005">
<REFERENCE NOTES="&lt;p&gt;DB - EMBASE&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Aras O, Karaduman A, Yilmaz O, Basoglu B</AU>
<TI>The effect of electrical stimulation on muscle strength in neuromuscular diseases. [Turkish]</TI>
<SO>Fizyoterapi Rehabilitasyon Vol 16(2)()(pp 45-50), 2005</SO>
<YR>2005</YR>
<VL>16</VL>
<NO>2</NO>
<PG>45-50</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="275"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Bean-2001" NAME="Bean 2001" YEAR="2001">
<REFERENCE NOTES="&lt;p&gt;Department of Physical Medicine and Rehabilitation, Harvard Medical School, and Spaulding Rehabilitation Hospital, Boston, Massachusetts, USAFAU - Bean, J&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bean J, Walsh A, Frontera W</AU>
<TI>Brace modification improves aerobic performance in Charcot-Marie-Tooth disease: a single-subject design</TI>
<SO>American Journal of Physical Medicine and Rehabilitation</SO>
<YR>2001</YR>
<VL>80</VL>
<NO>8</NO>
<PG>578-82</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="742"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-1992" NAME="Brown 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;Division of Plastic Surgery, Southern Illinois University School of Medicine, Springfield 62794-9230FAU - Brown, R E&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown RE, Zamboni WA, Zook EG, Russell RC</AU>
<TI>Evaluation and management of upper extremity neuropathies in Charcot-Marie-Tooth disease</TI>
<SO>Journal of Hand Surgery</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>3</NO>
<PG>523-30</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1654"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chetlin-2004b" NAME="Chetlin 2004b" YEAR="2004">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chetlin RD, Gutmann L, Tarnopolsky M, Ullrich IH, Yeater RA</AU>
<TI>Resistance training effectiveness in patients with Charcot-Marie-Tooth disease: recommendations for exercise prescription</TI>
<SO>Archive of Physical Medicine and Rehabilitation</SO>
<YR>2004</YR>
<VL>85</VL>
<NO>8</NO>
<PG>1217-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Congia-1991" NAME="Congia 1991" YEAR="1991">
<REFERENCE NOTES="&lt;p&gt;Cattedra di Patologia Speciale Neurologica della Universita di CagliariFAU - Congia, S&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Congia S, Tronci S, Ledda M, Porcella A, Coppola G</AU>
<TI>Low doses of TRH in amyotrophic lateral sclerosis and in other neurological diseases</TI>
<SO>Italian Journal of Neurological Sciences</SO>
<YR>1991</YR>
<VL>12</VL>
<NO>2</NO>
<PG>193-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1735"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dahl-2004" NAME="Dahl 2004" YEAR="2004">
<REFERENCE NOTES="&lt;p&gt;Seksjon for behandlingsreiser, Revmatologisk avdeling, og Nevrologisk avdeling, Rikshospitalet, Oslo arvedahl@rikshospitaletnoFAU - Dahl, Arve&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dahl A, Skjeldal OH, Simensen A, Dalen HE, Brathen T, Ahlvin P, et al</AU>
<TI>[Treatment of patients with neuromuscular disease in a warm climate]</TI>
<SO>Tidsskr Nor Laegeforen</SO>
<YR>2004</YR>
<VL>124</VL>
<NO>13-14</NO>
<PG>1795-8</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="334"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-de-Matas-2000" NAME="de Matas 2000" YEAR="2000">
<REFERENCE NOTES="&lt;p&gt;Walton Centre for Neurology and Neurosurgery, Liverpool, United KingdomFAU - de Matas, M&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>de Matas M, Francis P, Miles JB</AU>
<TI>Microvascular decompression for trigeminal neuralgia in Charcot-Marie-Tooth disease</TI>
<SO>Journal of Neurosurgery</SO>
<YR>2000</YR>
<VL>92</VL>
<NO>4</NO>
<PG>715-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="885"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dyck-1982a" NAME="Dyck 1982a" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dyck PJ, Swanson CJ, Low PA, Bartleson JD, Lambert EH</AU>
<TI>Prednisone-responsive hereditary motor and sensory neuropathy</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1982</YR>
<VL>57</VL>
<NO>4</NO>
<PG>239-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dyck-1982b" NAME="Dyck 1982b" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dyck PJ, Swanson CJ, Low PA</AU>
<TI>Prednisone-responsive hereditary motor and sensory neuropathy</TI>
<SO>Neurology</SO>
<YR>1982</YR>
<VL>32</VL>
<NO>4II</NO>
<PG>710</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Folkers-1985" NAME="Folkers 1985" YEAR="1985">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Folkers K, Wolaniuk J, Simonsen R, Morishita M, Vadhanavikit S</AU>
<TI>Biochemical rationale and the cardiac response of patients with muscle disease to therapy with coenzyme Q10</TI>
<SO>Proceedings of the National Academy of Sciences of the United States of America</SO>
<YR>1985</YR>
<VL>82</VL>
<NO>13</NO>
<PG>4513-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1937"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Folkers-1995" NAME="Folkers 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Institute for Biomedical Research, University of Texas at Austin 78705, USAFAU - Folkers, K&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Folkers K, Simonsen R</AU>
<TI>Two successful double-blind trials with coenzyme Q10 (vitamin Q10) on muscular dystrophies and neurogenic atrophies</TI>
<SO>Biochimica et Biophysica Acta</SO>
<YR>1995</YR>
<VL>1271</VL>
<NO>1</NO>
<PG>281-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1381"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jaradeh-1992" NAME="Jaradeh 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jaradeh S, Dyck PJ</AU>
<TI>Hereditary motor and sensory neuropathy with treatable extrapyramidal features</TI>
<SO>Archives of Neurology</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>2</NO>
<PG>175-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Lindeman-1994b" NAME="Lindeman 1994b" YEAR="1994">
<REFERENCE NOTES="&lt;p&gt;Department of Rehabilitation, University Hospital Maastricht, The NetherlandsFAU - Lindeman, E&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindeman E, Leffers P, Reulen J, Spaans F, Drukker J</AU>
<TI>Reduction of knee torques and leg-related functional abilities in hereditary motor and sensory neuropathy</TI>
<SO>Archives of Physical Medicine and Rehabilitation</SO>
<YR>1994</YR>
<VL>75</VL>
<NO>11</NO>
<PG>1201-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1436"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindeman-1998" NAME="Lindeman 1998" YEAR="1998">
<REFERENCE NOTES="&lt;p&gt;Department of Rehabilitation, University Hospital Utrecht/Rehabilitation Centre de Hoogstraat, The NetherlandsFAU - Lindeman, E&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindeman E, Leffers P, Reulen J, Spaans F, Drukker J</AU>
<TI>Quadriceps strength and timed motor performances in myotonic dystrophy, Charcot-Marie-Tooth disease, and healthy subjects</TI>
<SO>Clinical rehabilitation</SO>
<YR>1998</YR>
<VL>12</VL>
<NO>2</NO>
<PG>127-35</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1070"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lindeman-1999b" NAME="Lindeman 1999b" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;Department of Rehabilitation, University Hospital, Maastricht, Netherlands elindman@pmbrazunlFAU - Lindeman, E&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lindeman E, Spaans F, Reulen JP, Leffers P, Drukker J</AU>
<TI>Surface EMG of proximal leg muscles in neuromuscular patients and in healthy controls. Relations to force and fatigue</TI>
<SO>Journal of Electromyography and Kinesiology</SO>
<YR>1999</YR>
<VL>9</VL>
<NO>5</NO>
<PG>299-307</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="927"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lissett-1998" NAME="Lissett 1998" YEAR="1998">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lissett CA,Toogood AA, Didi M, Shalet SM</AU>
<TI>Growth hormone replacement in an adult with mild growth hormone deficiency and hereditary motor and sensory neuropathy: growth hormone restores independent mobility</TI>
<SO>Hormone Research</SO>
<YR>1998</YR>
<VL>50</VL>
<NO>4</NO>
<PG>232-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobzin-1986" NAME="Lobzin 1986" YEAR="1986">
<REFERENCE NOTES="&lt;p&gt;DB - EMBASE&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobzin VS, Saikova LA, Kosachev VD</AU>
<TI>Pathogenesis and treatment of neural amyotrophy [Russian]</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova</SO>
<YR>1986</YR>
<VL>86</VL>
<NO>11</NO>
<PG>1629-33</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6387"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobzin-1987" NAME="Lobzin 1987" YEAR="1987">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobzin VS, Saikova LA, Kosachev VD, Shiman AG</AU>
<TI>[Physical therapy of hereditary neuropathies]</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova</SO>
<YR>1987</YR>
<VL>87</VL>
<NO>3</NO>
<PG>342-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1903"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobzin-1988" NAME="Lobzin 1988" YEAR="1988">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobzin VS, Saikova LA, Shiman AG, Kosachev VD</AU>
<TI>[Treatment of patients with Charcot-Marie-Tooth neural amyotrophy]</TI>
<SO>Vrach Delo</SO>
<YR>1988</YR>
<VL>Dec.</VL>
<NO>12</NO>
<PG>73-4</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1846"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobzin-1990" NAME="Lobzin 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobzin VS, Saikova LA, Shiman AG, Kosachev VD</AU>
<TI>[A comparative evaluation of the efficacy of physical treatment methods in Charcot-Marie-Tooth neural amyotrophy]</TI>
<SO>Vopr Kurortol Fizioter Lech Fiz Kult</SO>
<YR>1990</YR>
<VL>Nov-Dec</VL>
<NO>6</NO>
<PG>53-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1758"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lobzin-1992" NAME="Lobzin 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lobzin VS, Zhulev NM, Kosachev VD, Tiukarkina AB, Badzgaradze I, Zavolokov IG</AU>
<TI>[Autonomic vascular disorders in neuropathies and the methods for their pathogenetic therapy]</TI>
<SO>Zhurnal Nevropatologii i Psikhiatrii Imeni S.S. Korsakova</SO>
<YR>1992</YR>
<VL>92</VL>
<NO>5-12</NO>
<PG>32-5</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1682"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mann-1992" NAME="Mann 1992" YEAR="1992">
<REFERENCE NOTES="&lt;p&gt;University of Wisconsin-MadisonFAU - Mann, D C&amp;#182;&lt;/p&gt;" PRIMARY="YES" TYPE="JOURNAL_ARTICLE">
<AU>Mann DC, Hsu JD</AU>
<TI>Triple arthrodesis in the treatment of fixed cavovarus deformity in adolescent patients with Charcot-Marie-Tooth disease</TI>
<SO>Foot &amp; Ankle</SO>
<YR>1992</YR>
<VL>13</VL>
<NO>1</NO>
<PG>1-6</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1675"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Miller-1982" NAME="Miller 1982" YEAR="1982">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Miller GM, Hsu JD, Hoffer MM, Rentfro R</AU>
<TI>Posterior tibial tendon transfer: a review of the literature and analysis of 74 procedures</TI>
<SO>Journal of Pediatric Orthopedics</SO>
<YR>1982</YR>
<VL>2</VL>
<NO>4</NO>
<PG>363-70</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1991"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oganesyan-1996" NAME="Oganesyan 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;NN Priorov Central Institute of Traumatology and Orthopaedics, Moscow, RussiaFAU - Oganesyan, O V&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oganesyan OV, Istomina IS, Kuzmin VI</AU>
<TI>Treatment of equinocavovarus deformity in adults with the use of a hinged distraction apparatus</TI>
<SO>The Journal of Bone and Joint Surgery. American Volume</SO>
<YR>1996</YR>
<VL>78</VL>
<NO>4</NO>
<PG>546-56</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1290"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Prensky-1984" NAME="Prensky 1984" YEAR="1984">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Prensky AL, Dodson WE</AU>
<TI>The steroid treatment of hereditary motor and sensory neuropathy</TI>
<SO>Neuropediatrics</SO>
<YR>1984</YR>
<VL>15</VL>
<NO>4</NO>
<PG>203-7</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1956"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Riley-1980" NAME="Riley 1980" YEAR="1980">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Riley WB, Mann RJ, Burkhalter WE</AU>
<TI>Extensor pollicis longus opponensplasty</TI>
<SO>Journal of Hand Surgery [Am.]</SO>
<YR>1980</YR>
<VL>5</VL>
<NO>3</NO>
<PG>217-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Russell-1995" NAME="Russell 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Department of Neurology, Mayo Clinic Rochester, Minnesota 55905, USAFAU - Russell, J W&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Russell JW, Windebank AJ, Harper CM</AU>
<TI>Treatment of stable chronic demyelinating polyneuropathy with 3,4-diaminopyridine</TI>
<SO>Mayo Clinic Proceedings</SO>
<YR>1995</YR>
<VL>70</VL>
<NO>6</NO>
<PG>532-39</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1378"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Saltzman-1999" NAME="Saltzman 1999" YEAR="1999">
<REFERENCE NOTES="&lt;p&gt;DA - 19991110&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Saltzman CL, Fehrle MJ, Cooper RR, Spencer EC, Ponseti IV</AU>
<TI>Triple arthrodesis: twenty-five and forty-four-year average follow-up of the same patients</TI>
<SO>The Journal of Bone and Joint Surgery. American Volume</SO>
<YR>1999</YR>
<VL>81</VL>
<NO>10</NO>
<PG>1391-1402</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="6388"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Trumble-1999" NAME="Trumble 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Trumble SJ, Mayo KA, Mast JW</AU>
<TI>The periacetabular osteotomy. Minimum 2 year followup in more than 100 hips</TI>
<SO>Clinical Orthopaedics and Related Research</SO>
<YR>1999</YR>
<VL>363</VL>
<PG>54-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wetmore-1989" NAME="Wetmore 1989" YEAR="1989">
<REFERENCE NOTES="&lt;p&gt;Department of Orthopaedic Surgery, Newington Children's HospitalFAU - Wetmore, R S&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wetmore RS, Drennan JC</AU>
<TI>Long-term results of triple arthrodesis in Charcot-Marie-Tooth disease</TI>
<SO>The Journal of Bone and Joint Surgery. American Volume</SO>
<YR>1989</YR>
<VL>71</VL>
<NO>3</NO>
<PG>417-22</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1832"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Williams-1986" NAME="Williams 1986" YEAR="1986">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Williams LL, O'Dougherty MM, Wright FS, Bobulski RJ, Horrocks LA</AU>
<TI>Dietary essential fatty acids, vitamin E, and Charcot-Marie-Tooth disease</TI>
<SO>Neurology</SO>
<YR>1986</YR>
<VL>36</VL>
<NO>9</NO>
<PG>1200-1205</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1911"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Wood-1995" NAME="Wood 1995" YEAR="1995">
<REFERENCE NOTES="&lt;p&gt;Department of Orthopaedic Surgery, Loma Linda University School of Medicine, California, USAFAU - Wood, V E&amp;#182;&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Wood VE, Huene D, Nguyen J</AU>
<TI>Treatment of the upper limb in Charcot-Marie-Tooth disease</TI>
<SO>Journal of Hand Surgery (Edinburgh, Lothian)</SO>
<YR>1995</YR>
<VL>20</VL>
<NO>4</NO>
<PG>511-18</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1366"/>
</IDENTIFIERS>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES/>
<ONGOING_STUDIES>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Blin" NAME="Blin" YEAR="2007">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Kurlemann" NAME="Kurlemann" YEAR="2007">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pareyson" NAME="Pareyson" YEAR="2006">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Shy" NAME="Shy" YEAR="2006">
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Verhamme" NAME="Verhamme" YEAR="2006">
<IDENTIFIERS/>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES>
<ADDITIONAL_REFERENCES>
<REFERENCE ID="REF-Adlkofer-1995" NAME="Adlkofer 1995" TYPE="JOURNAL_ARTICLE">
<AU>Adlkofer K, Martini R, Aguzzi A, Zielasek J, Toyka KV, Suter U</AU>
<TI>Hypermyelination and demyelinating peripheral neuropathy in Pmp22-deficient mice</TI>
<SO>Nature Genetics</SO>
<YR>1995</YR>
<VL>11</VL>
<NO>3</NO>
<PG>274-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Adlkofer-1997" NAME="Adlkofer 1997" TYPE="JOURNAL_ARTICLE">
<AU>Adlkofer K, Frei R, Neuberg DH, Zielasek J, Toyka KV, Suter U</AU>
<TI>Heterozygous peripheral myelin protein 22-deficient mice are affected by a progressive demyelinating tomaculous neuropathy</TI>
<SO>Journal of Neuroscience</SO>
<YR>1997</YR>
<VL>17</VL>
<NO>12</NO>
<PG>4662-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anderson-1996" NAME="Anderson 1996" TYPE="JOURNAL_ARTICLE">
<AU>Anderson RT, Aaronson NK, Bullinger M, McBee WL</AU>
<TI>A review of the progress towards developing health-related quality-of-life instruments for international clinical studies and outcomes research</TI>
<SO>Pharmacoeconomics</SO>
<YR>1996</YR>
<VL>10</VL>
<NO>4</NO>
<PG>336-55</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cornblath-1999" NAME="Cornblath 1999" TYPE="JOURNAL_ARTICLE">
<AU>Cornblath DR, Chaudhry V, Carter K, Lee D, Seysedadr M, Miernicki M, et al</AU>
<TI>Total neuropathy score: validation and reliability study</TI>
<SO>Neurology</SO>
<YR>1999</YR>
<VL>53</VL>
<NO>8</NO>
<PG>1660-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dyck-2005a" NAME="Dyck 2005a" TYPE="BOOK_SECTION">
<AU>Shy ME, Lupski JR, Chance PF, Klein CJ, Dyck PJ</AU>
<TI>Hereditary Motor And Sensory Neuropathy</TI>
<SO>Peripheral Neuropathy</SO>
<YR>2005</YR>
<VL>2</VL>
<PG>1623-58</PG>
<ED>Dyck PJ, Thomas PK</ED>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Dyck-2005b" NAME="Dyck 2005b" TYPE="BOOK_SECTION">
<AU>Dyck PJ, Hughes RAC, O'Brien PC</AU>
<TI>Quantitating overall neuropathic symptoms, impairments, and outcomes</TI>
<SO>Peripheral Neuropathy</SO>
<YR>2005</YR>
<PG>1031-52</PG>
<EN>4th</EN>
<ED>Dyck PJ, Thomas PK</ED>
<PB>WB Saunders</PB>
<CY>Philadelphia</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gabreels_x002d_Festen-1993" NAME="Gabreels-Festen 1993" TYPE="JOURNAL_ARTICLE">
<AU>Gabreels-Festen A, Gabreels F</AU>
<TI>Hereditary demyelinating motor and sensory neuropathy</TI>
<SO>Brain Pathology</SO>
<YR>1993</YR>
<VL>3</VL>
<NO>2</NO>
<PG>135-46</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Grandis-2005" NAME="Grandis 2005" TYPE="JOURNAL_ARTICLE">
<AU>Grandis M, Shy ME</AU>
<TI>Current therapy for Charcot-Marie-Tooth disease</TI>
<SO>Current Treatment Options in Neurology</SO>
<YR>2005</YR>
<VL>7</VL>
<NO>1</NO>
<PG>23-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hahn-2001" NAME="Hahn 2001" TYPE="JOURNAL_ARTICLE">
<AU>Hahn AF, Ainsworth PJ, Bolton CF, Bilbao JM, Vallat JM</AU>
<TI>Pathological findings in the x-linked form of Charcot-Marie-Tooth disease: a morphometric and ultrastructural analysis</TI>
<SO>Acta Neuropathologica (Berlin)</SO>
<YR>2001</YR>
<VL>101</VL>
<NO>2</NO>
<PG>129-39</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Harding-1980" NAME="Harding 1980" TYPE="JOURNAL_ARTICLE">
<AU>Harding AE, Thomas PK</AU>
<TI>The clinical features of hereditary motor and sensory neuropathy types I and II</TI>
<SO>Brain</SO>
<YR>1980</YR>
<VL>103</VL>
<NO>2</NO>
<PG>259-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayasaka-1993a" NAME="Hayasaka 1993a" TYPE="JOURNAL_ARTICLE">
<AU>Hayasaka K, Himoro M, Takada G, Takahashi E, Minoshima S, Shimizu N</AU>
<TI>Structure and localization of the gene encoding human peripheral myelin protein 2 (PMP2)</TI>
<SO>Genomics</SO>
<YR>1993</YR>
<VL>18</VL>
<PG>244-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayasaka-1993b" NAME="Hayasaka 1993b" TYPE="JOURNAL_ARTICLE">
<AU>Hayasaka K, Himoro M, Sawaishi Y, Nanao K, Takahashi T, Takada G, et al</AU>
<TI>De novo mutation of the myelin Po gene in Dejerine-Sottas disease (hereditary motor and sensory neuropathy type III)</TI>
<SO>Nature Genetics</SO>
<YR>1993</YR>
<VL>5</VL>
<PG>266-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hayasaka-1993c" NAME="Hayasaka 1993c" TYPE="JOURNAL_ARTICLE">
<AU>Hayasaka K, Ohnishi A, Takada G, Fukushima Y, Murai Y</AU>
<TI>Mutation of the myelin P0 gene in Charcot-Marie-tooth neuropathy type 1</TI>
<SO>Biochemical and Biophysical Research Communications</SO>
<YR>1993</YR>
<VL>194</VL>
<NO>3</NO>
<PG>1317-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Jenkinson-1993" NAME="Jenkinson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Jenkinson C, Coulter A, Wright L</AU>
<TI>Short form 36 (SF36) health survey questionnaire: normative data for adults of working age</TI>
<SO>British Medical Journal</SO>
<YR>1993</YR>
<VL>306</VL>
<NO>6890</NO>
<PG>1437-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krajewski-1999" NAME="Krajewski 1999" TYPE="JOURNAL_ARTICLE">
<AU>Krajewski K, Turansky C, Lewis R, Garbern J, Hinderer S, Kamholz J, et al</AU>
<TI>Correlation between weakness and axonal loss in patients with CMT1A</TI>
<SO>Annals of the New York Academy of Science</SO>
<YR>1999</YR>
<VL>883</VL>
<PG>490-2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Krajewski-2000" NAME="Krajewski 2000" TYPE="JOURNAL_ARTICLE">
<AU>Krajewski KM, Lewis RA, Fuerst DR, Turansky C, Hinderer SR, Garbern J, et al</AU>
<TI>Neurological dysfunction and axonal degeneration in Charcot-Marie-Tooth disease type 1A</TI>
<SO>Brain</SO>
<YR>2000</YR>
<VL>123</VL>
<NO>Pt 7</NO>
<PG>1516-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kuhlenbaumer-2002" NAME="Kuhlenbaumer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Kuhlenbaumer G, Young P, Hunermund G, Ringelstein B, Stogbauer F</AU>
<TI>Clinical features and molecular genetics of hereditary peripheral neuropathies</TI>
<SO>Journal of Neurology</SO>
<YR>2002</YR>
<VL>249</VL>
<NO>12</NO>
<PG>1629-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lupski-1991" NAME="Lupski 1991" TYPE="JOURNAL_ARTICLE">
<AU>Lupski J, de Oca-Luna R, Slaugenhaupt S, Pentao L, Guzzetta V, Trask BJ, et al</AU>
<TI>DNA duplication associated with Charcot-Marie-Tooth disease type 1A</TI>
<SO>Cell</SO>
<YR>1991</YR>
<VL>66</VL>
<NO>2</NO>
<PG>219-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lupski-1992" NAME="Lupski 1992" TYPE="JOURNAL_ARTICLE">
<AU>Lupski J, Wise C, Kuwano A, Pentao L, Parke J, Glaze DG, et al</AU>
<TI>Gene dosage is a mechanism for Charcot-Marie-Tooth disease type 1A</TI>
<SO>Nature Genetics</SO>
<YR>1992</YR>
<VL>1</VL>
<NO>1</NO>
<PG>29-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martini-1997" NAME="Martini 1997" TYPE="JOURNAL_ARTICLE">
<AU>Martini R</AU>
<TI>Animal models for inherited peripheral neuropathies</TI>
<SO>Journal of Anatomy</SO>
<YR>1997</YR>
<VL>191</VL>
<NO>Pt 3</NO>
<PG>321-36</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martini-2000" NAME="Martini 2000" TYPE="JOURNAL_ARTICLE">
<AU>Martini R</AU>
<TI>Animal models for inherited peripheral neuropathies: chances to find treatment strategies?</TI>
<SO>Journal of Neuroscience Research</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>3</NO>
<PG>244-50</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Martini-2001" NAME="Martini 2001" TYPE="JOURNAL_ARTICLE">
<AU>Martini R</AU>
<TI>The effect of myelinating Schwann cells on axons</TI>
<SO>Muscle &amp; Nerve</SO>
<YR>2001</YR>
<VL>24</VL>
<NO>4</NO>
<PG>456-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Maurer-2002" NAME="Maurer 2002" TYPE="JOURNAL_ARTICLE">
<AU>Maurer M, Kobsar I, Berghoff M, Schmid CD, Carenini S, Martini R</AU>
<TI>Role of immune cells in animal models for inherited neuropathies: facts and visions</TI>
<SO>Journal of Anatomy</SO>
<YR>2002</YR>
<VL>200</VL>
<NO>4</NO>
<PG>405-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Merkies-2000" NAME="Merkies 2000" TYPE="JOURNAL_ARTICLE">
<AU>Merkies IS, Schmitz PI, van der Meche FG, van Doorn PA</AU>
<TI>Psychometric evaluation of a new sensory scale in immune-mediated polyneuropathies. Inflammatory Neuropathy Cause and Treatment (INCAT) Group</TI>
<SO>Neurology</SO>
<YR>2000</YR>
<VL>54</VL>
<NO>4</NO>
<PG>943-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nelis-1996" NAME="Nelis 1996" TYPE="JOURNAL_ARTICLE">
<AU>Nelis E, Van Broeckhoven C, De Jonghe P, Lofgren A, Vandenberghe A, Latour P, et al</AU>
<TI>Estimation of the mutation frequencies in Charcot-Marie-Tooth disease type 1 and hereditary neuropathy with liability to pressure palsies: a European collaborative study</TI>
<SO>European Journal of Human Genetics</SO>
<YR>1996</YR>
<VL>4</VL>
<NO>1</NO>
<PG>25-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nicholson-1993" NAME="Nicholson 1993" TYPE="JOURNAL_ARTICLE">
<AU>Nicholson G, Nash J</AU>
<TI>Intermediate nerve conduction velocities define X-linked Charcot-Marie-Tooth neuropathy families</TI>
<SO>Neurology</SO>
<YR>1993</YR>
<VL>43</VL>
<NO>12</NO>
<PG>2558-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pareyson-2004" NAME="Pareyson 2004" TYPE="JOURNAL_ARTICLE">
<AU>Pareyson D</AU>
<TI>Differential diagnosis of Charcot-Marie-Tooth disease and related neuropathies</TI>
<SO>Neurological Science</SO>
<YR>2004</YR>
<VL>52</VL>
<NO>2</NO>
<PG>72-82</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pareyson-2006" NAME="Pareyson 2006" TYPE="JOURNAL_ARTICLE">
<AU>Pareyson D, Schenone A, Fabrizi GM, Santoro L, Padua L, Quattrone A, et al</AU>
<TI>A multicenter, randomized, double-blind, placebo-controlled trial of long-term ascorbic acid treatment in Charcot-Marie-Tooth disease type 1A (CMT-TRIAAL): the study protocol [EudraCT no.: 2006-000032-27]</TI>
<SO>Pharmacological Research</SO>
<YR>2006</YR>
<VL>54</VL>
<NO>6</NO>
<PG>436-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Passage-2004" NAME="Passage 2004" TYPE="JOURNAL_ARTICLE">
<AU>Passage E, Norreel JC, Noack-Fraissignes P, Sanguedolce V, Pizant J, Thirion X, et al</AU>
<TI>Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease</TI>
<SO>Nature Medicine</SO>
<YR>2004</YR>
<VL>10</VL>
<NO>4</NO>
<PG>396-401</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Reilly-2006" NAME="Reilly 2006" TYPE="JOURNAL_ARTICLE">
<AU>Reilly MM, de Jonghe P, Pareyson D</AU>
<TI>136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A)8-10 April 2005, Naarden, The Netherlands</TI>
<SO>Neuromuscular Disorders</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>6</NO>
<PG>396-402</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sereda-2003" NAME="Sereda 2003" TYPE="JOURNAL_ARTICLE">
<AU>Sereda MW, Meyer zu Horste G, Suter U, Uzma N, Nave KA</AU>
<TI>Therapeutic administration of progesterone antagonist in a model of Charcot-Marie-Tooth disease (CMT-1A)</TI>
<SO>Nature Medicine</SO>
<YR>2003</YR>
<VL>9</VL>
<NO>12</NO>
<PG>1533-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Shy-2005" NAME="Shy 2005" TYPE="JOURNAL_ARTICLE">
<AU>Shy ME, Blake J, Krajewski K, Fuerst DR, Laura M, Hahn AF, et al</AU>
<TI>Reliability and validity of the CMT neuropathy score as a measure of disability</TI>
<SO>Neurology</SO>
<YR>2005</YR>
<VL>64</VL>
<NO>7</NO>
<PG>1209-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Street-2003" NAME="Street 2003" TYPE="JOURNAL_ARTICLE">
<AU>Street VA, Bennett CL, Goldy JD, Shirk AJ, Kleopa KA, Tempel BL, et al</AU>
<TI>Mutation of a putative protein degradation gene LITAF/SIMPLE in Charcot- Marie-Tooth disease 1C</TI>
<SO>Neurology</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>22-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Suter-2003" NAME="Suter 2003" TYPE="JOURNAL_ARTICLE">
<AU>Suter U, Scherer SS</AU>
<TI>Disease mechanisms in inherited neuropathies</TI>
<SO>Nature Reviews Neuroscience</SO>
<YR>2003</YR>
<VL>4</VL>
<NO>9</NO>
<PG>714-26</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Timmerman-1992" NAME="Timmerman 1992" TYPE="JOURNAL_ARTICLE">
<AU>Timmerman V, Nelis E, Van Hul W, Nieuwenhuijsen B, Chen K, Wang S, et al</AU>
<TI>The peripheral myelin protein gene PMP-22 is contained within the Charcot-Marie-Tooth disease type 1A duplication</TI>
<SO>Nature Genetics</SO>
<YR>1992</YR>
<VL>1</VL>
<NO>3</NO>
<PG>171-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-van-der-Kooi-2005" NAME="van der Kooi 2005" TYPE="JOURNAL_ARTICLE">
<AU>van der Kooi EL, Lindeman E, Riphagen I</AU>
<TI>Strength training and aerobic exercise training for muscle disease</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<VL>The Cochrane Database of Systematic Reviews 2005</VL>
<NO>1</NO>
<PG>CD003907</PG>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="1"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-van-Swieten-1988" NAME="van Swieten 1988" TYPE="JOURNAL_ARTICLE">
<AU>van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, van Gijn J</AU>
<TI>Interobserver agreement for the assessment of handicap in stroke patients</TI>
<SO>Stroke</SO>
<YR>1988</YR>
<VL>19</VL>
<NO>5</NO>
<PG>604-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Verhoeven-2006" NAME="Verhoeven 2006" TYPE="JOURNAL_ARTICLE">
<AU>Verhoeven K, Claeys KG, Zuchner S, Schroder JM, Weis J, Ceuterick C, et al</AU>
<TI>MFN2 mutation distribution and genotype/phenotype correlation in Charcot-Marie-Tooth type 2</TI>
<SO>Brain</SO>
<YR>2006</YR>
<VL>129</VL>
<NO>Pt 8</NO>
<PG>2093-102</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-White-2004" NAME="White 2004" TYPE="COCHRANE_REVIEW">
<AU>White CM, Pritchard J, Turner-Stokes L</AU>
<TI>Exercise for people with peripheral neuropathy</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>4</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="MEDLINE" VALUE="8"/>
<IDENTIFIER TYPE="OTHER" VALUE="CD003904"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Young-2001" NAME="Young 2001" TYPE="JOURNAL_ARTICLE">
<AU>Young P, Suter U</AU>
<TI>Disease mechanisms and potential therapeutic strategies in Charcot-Marie-Tooth disease</TI>
<SO>Brain Research. Brain Research Reviews</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>2-3</NO>
<PG>213-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Young-2003" NAME="Young 2003" TYPE="JOURNAL_ARTICLE">
<AU>Young P, Suter U</AU>
<TI>The causes of Charcot-Marie-Tooth disease</TI>
<SO>Cellular and Molecular Life Sciences</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>12</NO>
<PG>2547-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Zuchner-2004" NAME="Zuchner 2004" TYPE="JOURNAL_ARTICLE">
<AU>Zuchner S, Mersiyanova IV, Muglia M, Bissar-Tadmouri N, Rochelle J, Dadali EL et al</AU>
<TI>Mutations in the mitochondrial GTPase mitofusin 2 cause Charcot-Marie-Tooth neuropathy type 2A</TI>
<SO>Nature Genetics</SO>
<YR>2004</YR>
<VL>36</VL>
<NO>5</NO>
<PG>449-51</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES>
<CHARACTERISTICS_OF_INCLUDED_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR STUDY_ID="STD-Bradley-1988">
<CHAR_METHODS>
<P>Randomised double-blind trial. <BR/>Method of randomisation not given. </P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>Two groups with 15 CMT participants each. CMT 1 and CMT2 included diagnosed clinically and electrophysiologically, no genetic testing.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Initially 2 months placebo in both arms followed by 40mg. <BR/>Cronassial versus placebo for 5 months followed by Cronassial 40mg versus 100mg for another 5 months, no wash out phase in between, mode of administration i.m. <BR/>12 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Sensory measures, strength measures, EMG, Nerve conduction velocities and sensory and motor action potentials.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>1 drop out because of allergic rash under 100 mg Cronnassial, 1 drop out because of pain at injection site under 40 mg after 8 months.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Burns-2006">
<CHAR_METHODS>
<P>Randomised controlled trial. Method of randomisation central computer based.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>In total inclusion of 7 genetically proven CMT1A participants.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Custom foot orthoses for 3 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Foot pain, foot function and physical functioning, general health, vitality and social functioning as secondary outcomes.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>Subgroup analysis was given on request. <BR/>AE were not recorded seperately for CMT group.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Chetlin-2004">
<CHAR_METHODS>
<P>Randomised double-blind trial testing combination of resistance training and creatine. Method of randomisation was given on request.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>CMT1 and CMT2 patients based on clinical, electrophysiological and genetic diagnosis, 10 patients allocated to each group.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>One group performing resistance training daily in combination with additional oral intake of 5mg creatine per day, one group receiving resistance training in combination with placebo<BR/>12 weeks.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle fibre typing and size, quantitative muscle assessment.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>3 participants reported to have decreased their training due to delayed onset soreness.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Doherty-2001">
<CHAR_METHODS>
<P>Randomised double-blind placebo controlled cross-over trial. Method of randomisation unclear.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>A total of 39 CMT1 and CMT2 participants based on clincal, electrophysiological and genetic diagnosis.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>5mg creatine orally taken per day versus placebo, before cross over 5 week wash out.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Maximal voluntary strength, fatigue, 30-m timed walking, stair climbing.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>In the placebo group, side effects gastrointestinal upset and leg cramps in both groups, 1 drop out due to unrelated illness, 1 drop out due to muscle cramps.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lindeman-1995">
<CHAR_METHODS>
<P>Randomised controlled single blind trial.<BR/>Method of randomisation was given on request.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>29 participants in total either CMT1 or CMT2 based on clinical data.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>One group strength training for 24 weeks, control group no strength training.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle strength voluntary contraction, isokinetic knee torques, timed functional activities.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>One drop out from exercise group due to knee problems.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lindeman-1999">
<CHAR_METHODS>
<P>Randomised controlled single blind trial. <BR/>Method of randomisation was given on request<BR/>(same study as Lindeman 1995)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>29 participants in total either CMT1 or CMT2 based on clinical data.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>One group strength training for 24 weeks, control group no strength training.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle strength voluntary contraction, isokinetic knee torques, timed functional activities.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>One drop out from exercise group due to knee problems.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Lindemann-1994">
<CHAR_METHODS>
<P>Randomised controlled single blind trial. <BR/>Method of randomisation was given on request<BR/>(same study as Lindeman 1995)</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>29 participants in total either CMT1 or CMT2 based on clinical data.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Randomised controlled single blind trial. <BR/>Method of randomisation was given on request<BR/>(same study as Lindeman 1995).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Muscle strength voluntary contraction, isokinetic knee torques, timed functional activities.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>One drop out from exercise group due to knee problems.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Sahenk-2005">
<CHAR_METHODS>
<P>Randomised controlled double-blind trial.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS>
<P>8 patients with CMT1A carrying the duplication on chromosome 17p11.2 harbouring the PMP22 gene.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>One group 50 µg/ kg 3x/w recombinant human NT-3 subcutaneously.<BR/>Control group placebo injections for 6 months.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Nerve biopsies, Neuropathy impairment scale, pegboard test, density of myelinated fibers and Schwann cells in sural nerve biopsies.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES>
<P>No drop outs</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR STUDY_ID="STD-Smith-2006">
<CHAR_METHODS>
<P>Describes the same study as Chetlin 2004</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES>
<P>Myosin heavy chain content.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES/>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES SORT_BY="STUDY">
<EXCLUDED_CHAR STUDY_ID="STD-Aras-2005">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Electric stimulation in four children suffering from unspecified CMT. Outcome measure: 10 minute timed walking and fatigue.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Bean-2001">
<CHAR_REASON_FOR_EXCLUSION>
<P>Single subject study analysing effect of brace modification on aerobic exercise.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Brown-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Retrospective evaluation of upper limb neuropathies in CMT. No intervention done. No report on adverse effects.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Chetlin-2004b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Trial describes same participants as in Chetlin 2004 without creatine monohydrate supplementation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Congia-1991">
<CHAR_REASON_FOR_EXCLUSION>
<P>TRH low dose treatment for a total of two weeks in four unspecified CMT patients. Observational period too short.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dahl-2004">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Comparison of the effect of physiotherapy in a group of patients with neuromuscular diseases including 21 CMT patients and two Dejerine-Sottas patients in warm climate.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-de-Matas-2000">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Description of three CMT patients suffering from trigeminal neuralgia and the effect of microvascular decompression.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dyck-1982a">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, case series.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Dyck-1982b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, case series. Same trial as Dyck 1982</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Folkers-1985">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Cardiac response to Coenzme Q in a group of patients with neuromuscular disease including four patients with unspecified CMT. Design remains unclear.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Folkers-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Double-blinded study assessing the effect of 100mg coenzyme Q and physical performance per day on cardiac function. Three unspecified CMT patients included.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Jaradeh-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindeman-1994b">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindeman-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>No intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lindeman-1999b">
<CHAR_REASON_FOR_EXCLUSION>
<P>No intervention.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lissett-1998">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case description, growth hormone replacement</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lobzin-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lobzin-1987">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Open comparison of 118 CMT patients either receiving electrophoresis and benzohexonium versus treatment with electrophoresis and benzohexonium without different changing electrophoresis protocol.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lobzin-1988">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lobzin-1990">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. A comparative evaluation of the efficancy of physical treatment methods in unspecified CMT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Lobzin-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Autonomic vascular changes in a huge group of neuropathies including 315 CMT patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Mann-1992">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, case series, 10 unspecified CMT patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Miller-1982">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial, retrospective case series, five feet in three unspecified CMT patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Oganesyan-1996">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Retrospective analysis of the treatment with a Hinged distraction apparatus in a group of patients including three unspecified CMT patients suffering from pes equinovarus. No subgroup analysis given.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Prensky-1984">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. High dose of steroid in 10 CMT1 and 2 CMT2 patients. Cross-over design. Initially blinded but blinding was impossible due to severe side effects. Study had to be stopped due to serious side effects at a dose of 45-60mg/sqM methylprednisolone</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Riley-1980">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Russell-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>RCT but treatment and observational period was just four days and another four days in a cross over design in 27 CMT1 patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Saltzman-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Retrospective evaluation of a group of patients suffering from different diseases who had received triple arthrodesis. No CMT specific subgroup analysis.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Trumble-1999">
<CHAR_REASON_FOR_EXCLUSION>
<P>Case series including unspecified CMT patients.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wetmore-1989">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Retospective evaluation of 16 CMT patients after having received triple arthrodeses.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Williams-1986">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Linoleic acid, vitamin E and supplementation in 20 CMT 1 patients with matched controls. Nerve conduction velocities after one year Neuropathy disability scale after one year.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR STUDY_ID="STD-Wood-1995">
<CHAR_REASON_FOR_EXCLUSION>
<P>Not a randomised controlled trial. Retrospective analysis of different upper limb surgical treatments in clinical CMT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<ONGOING_CHAR STUDY_ID="STD-Blin">
<CHAR_STUDY_NAME>
<P>Information requested</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS/>
<CHAR_INTERVENTIONS/>
<CHAR_OUTCOMES/>
<CHAR_STARTING_DATE/>
<CHAR_CONTACT_INFORMATION/>
<CHAR_NOTES>
<P>Personal communication</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Kurlemann">
<CHAR_STUDY_NAME>
<P>Single center randomized double blind placebo controlled</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>CMT1A patients genetically carrying the duplication on chromosome 17q11.2 between 5-16 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ascorbic acid for 2 years in a dose of 1500 mg/day versus placebo.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Charcot-Marie-Tooth neuropathy scale</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>September 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Prof. Dr . G. Kurlemann, Dept. for Pediatric medicine, Neuropediatrics, Albert-Schweitzer-Str. 33, 48129 Münster <BR/>Prof. Dr. P. Young and Dr. G. Kuhlenbäumer<BR/>Department of Neurology, University of Muenster, Albert-Schweitzer-Str- 33, 48129 Muenster, Tel: +49-251-8348331, Fax: +49-251-8348181, young@uni-muenster.de, gkuhlen@uni-munester.de</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Personal communication</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Pareyson">
<CHAR_STUDY_NAME>
<P>A multicenter, randomized, double-blind, placebo-controlled trial of long term ascorbic acid in Charcot-Marie-tooth disease type 1A (CMT-TRIAAL)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>CMT1A patients genetically carrying the duplication on chromosome 17q11.2 between 18-70 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ascorbic acid for 2 years in a dose of 1500 mg/day versus placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Charcot-Marie-Tooth neuropathy scale , MVIC, 10m walking, nine-hole-peg test, ONLS, VAS for pain and fatigue, SF36, skin biopsy (expression of PMP22)</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>Autumn 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Dr. D. Pareyson, Department of Biochemistry and Genetics, C. Besta National Neurological Institute, Via Celoria11, 20133 Milan, Italy <BR/>Tel: +390223943001<BR/>Fax +39022664236<BR/>e-mail: dpareys@istituto-besta.it</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Pareyson 2006</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Shy">
<CHAR_STUDY_NAME>
<P>A Randomized, placebo-controlled, double masked 120 subject "Futility Design" clinical trial of Ascorbic acid treatment of Charcot-Marie-Tooth Disease Type 1A.</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>CMT1A patients genetically carrying the duplication on chromosome 17q11.2 between 18-70 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ascorbic acid (Vitamin C) (4 grams/day).</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Mean change in the CMT Neuropathy Scale following high dose ascorbic acid ingestion, assessed at baseline and every 6 months throughout the trial. (Time Frame: 25 months per subject from baseline to completion).CMT-Neuropathy scale as primary outcome. <BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>April 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>United States, Maryland<BR/> Johns Hopkins University, Dept of Neurology, Baltimore, Maryland, 21287, United States; Recruiting<BR/>Lora Clawson 410-624-4346 lclawson@jhmi.edu <BR/>Ahmet Hoke, MD, Principal Investigator</P>
<P>United States, Michigan<BR/> Wayne State University, Dept of Neurology, Detroit, Michigan, 48201, United States; Recruiting<BR/>Lisa Rowe 313-577-1689 lrowe@med.wayne.edu <BR/>Michael Shy, MD, Principal Investigator</P>
<P>United States, New York<BR/> University of Rochester Medical Center, Dept of Neurology, Rochester, New York, 14642, United States; Recruiting<BR/>Patty Smith 585-275-0581 Patty_Smith@urmc.rochester.edu <BR/>David Herrmann, MD, Principal Investigator</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Listed at ClinicalTrials.gov</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR STUDY_ID="STD-Verhamme">
<CHAR_STUDY_NAME>
<P>Ascorbic Acid Treatment in CMT1A Trial (AATIC)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS/>
<CHAR_PARTICIPANTS>
<P>CMT1A patients genetically carrying the duplication on chromosome 17q11.2 between 12-25 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS>
<P>Ascorbic acid for 1 year.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES>
<P>Change in motor nerve conduction velocity of the median nerve after 1 year primary outcome,<BR/>Secondary Outcome Measures: </P>
<P> * Change in minimal F response latency of the median nerve after 1 year.<BR/> * Changes in compound muscle action potential amplitude and area after 1 year.<BR/> * Change in motor unit number estimation of the abductor pollicis brevis muscle after 1 year.<BR/> * Changes in handgrip strength, strength of armflexors, foot dorsiflexors, knee extensors and hip flexors after 1 year.<BR/> * Change in overall disability sum score after 1 year.<BR/> * Change in AMC Linear Disability Scale score after 1 year.<BR/> * Evaluation of serum ascorbic acid concentrations during 1 year.<BR/> * Evaluation of side effects during 1 year.<BR/>
</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE>
<P>January 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION>
<P>Department of Neurology Academic Medical Center University of Amsterdam, Amsterdam, P.O.Box 22660, 1100 DD, Netherlands; Recruiting<BR/>C. Verhamme, MD +31-20-5663856 c.verhamme@amc.uva.nl</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_NOTES>
<P>Listed at ClinicalTrials.gov</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES>
<P>Ascorbic acid in CMT1A trial (AATIC) <BR/>Maximum voluntary isometric contraction (MVIC)<BR/>Academic medical center Linear Disability Scale (AMC Linear Disability Scale)<BR/>Visual analog scale (VAS) <BR/>Overall neuropathy limitations scale (ONLS)</P>
<P>
<BR/>
</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Bradley-1988">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Burns-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Chetlin-2004">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="UNKNOWN" STUDY_ID="STD-Doherty-2001">
<DESCRIPTION>
<P>B - Unclear</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lindeman-1995">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lindeman-1999">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Lindemann-1994">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Sahenk-2005">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY RESULT="YES" STUDY_ID="STD-Smith-2006">
<DESCRIPTION>
<P>A - Adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES MODIFIED="2008-04-27 17:04:25 +0100" MODIFIED_BY="[Empty name]">
<ADDITIONAL_TABLE ID="TBL-01" NO="1">
<TITLE>Methodological quality</TITLE>
<TABLE COLS="7" ROWS="8">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Randomisation</P>
</TH>
<TH>
<P>Concealed allocation</P>
</TH>
<TH>
<P>Follow up</P>
</TH>
<TH>
<P>Blinding observer</P>
</TH>
<TH>
<P>Blinding patient</P>
</TH>
<TH>
<P>Inclusion criteria</P>
</TH>
</TR>
<TR>
<TD>
<P>Bradley 1988</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>C</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD>
<P>Burns 2006</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>D</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD>
<P>Chetlin 2004</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD>
<P>Doherty 2001</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>B</P>
</TD>
</TR>
<TR>
<TD>
<P>Lindeman 1995</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>D</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD>
<P>Sahenk</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
<TR>
<TD>
<P>Smith 2006</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>B</P>
</TD>
<TD>
<P>A</P>
</TD>
<TD>
<P>A</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-02" MODIFIED="2008-04-27 17:04:25 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE>Adverse events for interventions with drugs or food supplements</TITLE>
<TABLE COLS="5" ROWS="11">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Major adverse events</P>
</TH>
<TH>
<P>Minor adverse events</P>
</TH>
</TR>
<TR>
<TD>
<P>Bradley 1988</P>
</TD>
<TD>
<P>Purified bovine brain gangliosides (Cronassial), five months 40 mg Cronassial versus five months 100mg Cronassial versus placebo</P>
</TD>
<TD>
<P>30 CMT (clinical)</P>
</TD>
<TD>
<P>Allergic rash seen with 100mg in 2 patients, pain at injection site in one patient</P>
</TD>
<TD>
<P>16.9% increased pain with medication versus 7.4% in the placebo group, 2.7% redness/itching versus 0.9% in placebo group, 6.8% skin rash versus 2.7% in the placebo group, tinnitus at the dose of 100mg in 2.7% versus 0.3% in the placebo group.</P>
</TD>
</TR>
<TR>
<TD>
<P>Smith 2006, Chetlin 2004</P>
</TD>
<TD>
<P>Creatine monohydrate 5g/d combined with exercise</P>
</TD>
<TD>
<P>39 CMT patients</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>Mild gastrointestinal upset, leg cramps, fatigue, delayed-onset soreness.</P>
</TD>
</TR>
<TR>
<TD>
<P>Sahenk 2005</P>
</TD>
<TD>
<P>Neurotrophin-3 starting with 50 µg/kg increasing up to 150 µg/kg</P>
</TD>
<TD>
<P>4 CMT1A (genetically proven)</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>Irritation at injection site, mild diarrhoea.</P>
</TD>
</TR>
<TR>
<TD>
<P>Prensky 1984</P>
</TD>
<TD>
<P>Methylprednisolone 40 to 60 mg/m2</P>
</TD>
<TD>
<P>14 CMT clinical</P>
</TD>
<TD>
<P>Weight gain of 15 to 18 pounds in 3 patients, proximal myopathy and psychiatric illness in 1 patient (drop out), compression fracture of dorsal vertebrae T-12 due to significant worsening of osteoporosis in 1 patient, severe leg cramps in 1 patient, pseudotumour when steroid was stopped in 1 patient, depression in 1 patient, hypertrophic nerve root in one patient.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Russell 1995</P>
</TD>
<TD>
<P>3,4-diaminopyridine (3,4-DAP) 4x5mg/day up to 4x20mg/day</P>
</TD>
<TD>
<P>27 CMT patients (clinical)</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>71% facial pain and predominantly perioral parasthesia with a maximum duration of 90 minutes, 29% muscle fatigue, 18% nauseas and abdominal discomfort, 15% insomnia, 12% transient urinary frequency, 6% increased tearing or nasal dicharge, 6% facial flushing, 6% transient hand tremor or muscle twitching, 6% headache, 6% transient parageusia.</P>
</TD>
</TR>
<TR>
<TD>
<P>Dyck 1982a, Dyck 1982b</P>
</TD>
<TD>
<P>Prednisone</P>
</TD>
<TD>
<P>Single cases</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Folkers 1985, Folkers 1995</P>
</TD>
<TD>
<P>Q10</P>
</TD>
<TD>
<P>Single cases</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Lisett 1998</P>
</TD>
<TD>
<P>Growth hormone replacement</P>
</TD>
<TD>
<P>Single case</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Jaradeh 1992</P>
</TD>
<TD>
<P>Levodopa</P>
</TD>
<TD>
<P>6 unspecified CMT cases.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Williams 1986</P>
</TD>
<TD>
<P>Vitamin E combined with Cis-linolein, gamma-linoleic, oleic acid</P>
</TD>
<TD>
<P>20 CMT patients (clinical).</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
<ADDITIONAL_TABLE ID="TBL-03" MODIFIED="2008-04-27 17:04:25 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE>Adverse events for non-drug, non surgical interventions</TITLE>
<TABLE COLS="5" ROWS="8">
<TR>
<TH>
<P>Study</P>
</TH>
<TH>
<P>Intervention</P>
</TH>
<TH>
<P>Patients</P>
</TH>
<TH>
<P>Major adverse events</P>
</TH>
<TH>
<P>Minor adverse events</P>
</TH>
</TR>
<TR>
<TD>
<P>Lindeman 1998, Lindeman 1994b, Lindeman 1995, Lindeman 1999</P>
</TD>
<TD>
<P>Strength training</P>
</TD>
<TD>
<P>29 CMT patients</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>1 drop out due to knee problems, complaints owing to overuse.</P>
</TD>
</TR>
<TR>
<TD>
<P>Burns 2006</P>
</TD>
<TD>
<P>Foot orthoses</P>
</TD>
<TD>
<P>16 CMT</P>
</TD>
<TD>
<P>None reported specifically for CMT.</P>
</TD>
<TD>
<P>None specific for CMT group, additional foot pain in 12% of total number of (154) participants, ankle instability and foot irritation.</P>
</TD>
</TR>
<TR>
<TD>
<P>Bean 2001</P>
</TD>
<TD>
<P>Ankle foot orthoses</P>
</TD>
<TD>
<P>1 CMT patient</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Aras 2005</P>
</TD>
<TD>
<P>Exercise and electrical stimulation</P>
</TD>
<TD>
<P>4 CMT patients</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Dahl 2004</P>
</TD>
<TD>
<P>Treatment in warm climate</P>
</TD>
<TD>
<P>21 CMT patients</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P>Lobzin 1986; Lobzin 1987; Lobzin 1988; Lobzin 1990; Lobzin 1992</P>
</TD>
<TD>
<P>Proserin in electrophoresis with benzohexonium, and sine modelled electricity in electrophoresis with benzohexonium</P>
</TD>
<TD>
<P>433 CMT patients</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
<TD>
<P>None reported.</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
</TR>
</TABLE>
<FOOTNOTES/>
</ADDITIONAL_TABLE>
</ADDITIONAL_TABLES>
<ANALYSES_AND_DATA CALCULATED_DATA="YES">
<COMPARISON ID="CMP-001" NO="1">
<NAME>Neurotrophin-3 versus placebo</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="-5.226727871230044" CI_START="-13.773272128769957" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-9.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="1.3171484368034823E-5" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="4" UNITS="" WEIGHT="100.0" Z="4.357236630864908">
<NAME>Neuropathy impairment score</NAME>
<GROUP_LABEL_1>Neurotrophin-3</GROUP_LABEL_1>
<GROUP_LABEL_2>placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Neurotrophin-3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-5.226727871230044" CI_START="-13.773272128769957" EFFECT_SIZE="-9.5" ESTIMABLE="YES" MEAN_1="-8.5" MEAN_2="1.0" ORDER="25376" SD_1="1.91" SD_2="3.92" SE="2.180280945199494" STUDY_ID="STD-Sahenk-2005" TOTAL_1="4" TOTAL_2="4" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.4197644627854595" CI_START="-2.4197644627854595" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-0.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.6097222920178649" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="4" UNITS="" WEIGHT="100.0" Z="0.5104699098597407">
<NAME>Neuropathy impairment score motor</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>NT-3</GROUP_LABEL_2>
<GRAPH_LABEL_1>Neurotrophin-3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.4197644627854598" CI_START="-2.4197644627854595" EFFECT_SIZE="-0.5" ESTIMABLE="YES" MEAN_1="-0.8" MEAN_2="-0.3" ORDER="25377" SD_1="1.5" SD_2="1.26" SE="0.9794896630388705" STUDY_ID="STD-Sahenk-2005" TOTAL_1="4" TOTAL_2="4" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.515378697944091" CI_START="-8.084621302055908" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.004180580112092748" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="4" UNITS="" WEIGHT="100.0" Z="2.864204503546183">
<NAME>Neuropathy impairment score sensory</NAME>
<GROUP_LABEL_1>Placebo</GROUP_LABEL_1>
<GROUP_LABEL_2>NT-3</GROUP_LABEL_2>
<GRAPH_LABEL_1>Neurotrophin-3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.515378697944091" CI_START="-8.084621302055908" EFFECT_SIZE="-4.8" ESTIMABLE="YES" MEAN_1="-4.5" MEAN_2="0.3" ORDER="25378" SD_1="2.38" SD_2="2.36" SE="1.675857989210303" STUDY_ID="STD-Sahenk-2005" TOTAL_1="4" TOTAL_2="4" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="-1.3487521321807532" CI_START="-7.651247867819247" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.00512865764524332" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="4" TOTAL_2="4" UNITS="" WEIGHT="100.00000000000001" Z="2.7988397931178364">
<NAME>Neuropathy impairment score reflex</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Neurotrophin-3</GRAPH_LABEL_1>
<GRAPH_LABEL_2>placebo</GRAPH_LABEL_2>
<CONT_DATA CI_END="-1.3487521321807532" CI_START="-7.651247867819247" EFFECT_SIZE="-4.5" ESTIMABLE="YES" MEAN_1="-3.5" MEAN_2="1.0" ORDER="25379" SD_1="2.89" SD_2="1.41" SE="1.6078090682665027" STUDY_ID="STD-Sahenk-2005" TOTAL_1="4" TOTAL_2="4" WEIGHT="100.00000000000001"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" NO="2">
<NAME>Strength training versus no training</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="30.290443825382205" CI_START="5.109556174617792" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="17.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.00586253508619861" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="2.7553724878563473">
<NAME>Isokinetic knee torque extension</NAME>
<GROUP_LABEL_1>Strength training</GROUP_LABEL_1>
<GROUP_LABEL_2>No training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours training</GRAPH_LABEL_2>
<CONT_DATA CI_END="30.290443825382205" CI_START="5.109556174617792" EFFECT_SIZE="17.7" ESTIMABLE="YES" MEAN_1="12.4" MEAN_2="-5.3" ORDER="25380" SD_1="15.4" SD_2="17.3" SE="6.423813868363919" STUDY_ID="STD-Lindeman-1995" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="11.90732756759689" CI_START="0.29267243240310936" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.1" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.03951910680447582" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="2.0587404733984567">
<NAME>Isokinetic knee torque flexion</NAME>
<GROUP_LABEL_1>Strength training</GROUP_LABEL_1>
<GROUP_LABEL_2>No training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours training</GRAPH_LABEL_2>
<CONT_DATA CI_END="11.90732756759689" CI_START="0.29267243240310936" EFFECT_SIZE="6.1" ESTIMABLE="YES" MEAN_1="5.0" MEAN_2="-1.1" ORDER="25381" SD_1="7.3" SD_2="7.8" SE="2.962976673757451" STUDY_ID="STD-Lindeman-1995" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="26.70943712419684" CI_START="-1.5094371241968378" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.600000000000001" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.08006902509202213" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="1.7502857121673057">
<NAME>Maximal voluntary contraction</NAME>
<GROUP_LABEL_1>Strength training</GROUP_LABEL_1>
<GROUP_LABEL_2>No training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours no training</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours training</GRAPH_LABEL_2>
<CONT_DATA CI_END="26.70943712419684" CI_START="-1.5094371241968378" EFFECT_SIZE="12.600000000000001" ESTIMABLE="YES" MEAN_1="16.6" MEAN_2="4.0" ORDER="25382" SD_1="19.7" SD_2="16.9" SE="7.198824690397517" STUDY_ID="STD-Lindeman-1995" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="1.1676191355656909" CI_START="0.232380864434309" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.7" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.04" NO="4" P_CHI2="1.0" P_Q="1.0" P_Z="0.0033466975558619585" Q="0.0" RANDOM="NO" SCALE="10.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="13" TOTAL_2="13" UNITS="" WEIGHT="100.0" Z="2.9339577549971825">
<NAME>Walking 6m (comfortable)</NAME>
<GROUP_LABEL_1>Strength trianing</GROUP_LABEL_1>
<GROUP_LABEL_2>No training</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="1.1676191355656909" CI_START="0.232380864434309" EFFECT_SIZE="0.7" ESTIMABLE="YES" MEAN_1="1.0" MEAN_2="0.3" ORDER="25383" SD_1="0.5" SD_2="0.7" SE="0.23858557568108957" STUDY_ID="STD-Lindeman-1995" TOTAL_1="13" TOTAL_2="13" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" NO="3">
<NAME>Custom foot orthoses versus sham insoles</NAME>
<CONT_OUTCOME CHI2="0.0" CI_END="46.89030290416694" CI_START="-21.09030290416694" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="12.899999999999999" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.01" NO="1" P_CHI2="1.0" P_Q="1.0" P_Z="0.45696992836157535" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="0.7438455453560298">
<NAME>Foot pain</NAME>
<GROUP_LABEL_1>Custom orthoses</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham insole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours sham insole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours orthoses</GRAPH_LABEL_2>
<CONT_DATA CI_END="46.89030290416694" CI_START="-21.09030290416694" EFFECT_SIZE="12.899999999999999" ESTIMABLE="YES" MEAN_1="26.9" MEAN_2="14.0" ORDER="25384" SD_1="35.9" SD_2="32.4" SE="17.342309946651117" STUDY_ID="STD-Burns-2006" TOTAL_1="7" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="27.245517672839327" CI_START="-15.245517672839327" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="6.0" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.02" NO="2" P_CHI2="1.0" P_Q="1.0" P_Z="0.5799085207525349" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="9" UNITS="" WEIGHT="100.0" Z="0.5535183509448799">
<NAME>Function</NAME>
<GROUP_LABEL_1>Custom orthoses</GROUP_LABEL_1>
<GROUP_LABEL_2>Sham insole</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours shame insole</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours orthoses</GRAPH_LABEL_2>
<CONT_DATA CI_END="27.245517672839327" CI_START="-15.245517672839327" EFFECT_SIZE="6.0" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="5.6" ORDER="25385" SD_1="25.4" SD_2="15.1" SE="10.839749016013181" STUDY_ID="STD-Burns-2006" TOTAL_1="7" TOTAL_2="9" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="21.68902877708394" CI_START="-12.08902877708394" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="4.8" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.03" NO="3" P_CHI2="1.0" P_Q="1.0" P_Z="0.577501618189638" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.5570377817436946">
<NAME>Physical functioning</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours controle</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sham insole</GRAPH_LABEL_2>
<CONT_DATA CI_END="21.68902877708394" CI_START="-12.08902877708394" EFFECT_SIZE="4.8" ESTIMABLE="YES" MEAN_1="4.8" MEAN_2="0.0" ORDER="25386" SD_1="22.1" SD_2="5.6" SE="8.617009756455957" STUDY_ID="STD-Burns-2006" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="4.10845490731623E-34" CI_END="23.370840916847115" CI_START="-19.570840916847118" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="1.8999999999999997" ESTIMABLE="YES" I2="100.0" I2_Q="0.0" ID="CMP-003.04" NO="4" P_CHI2="0.0" P_Q="1.0" P_Z="0.8623045273895098" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.17344134703658096">
<NAME>General health</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sham insole</GRAPH_LABEL_2>
<CONT_DATA CI_END="23.370840916847115" CI_START="-19.570840916847118" EFFECT_SIZE="1.8999999999999995" ESTIMABLE="YES" MEAN_1="8.6" MEAN_2="6.7" ORDER="25387" SD_1="24.8" SD_2="15.0" SE="10.954711967263872" STUDY_ID="STD-Burns-2006" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="23.086457116690056" CI_START="-2.6864571166900557" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="10.2" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.05" NO="5" P_CHI2="1.0" P_Q="1.0" P_Z="0.12081360412885007" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="1.5513676459929502">
<NAME>Vitality</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sham insole</GRAPH_LABEL_2>
<CONT_DATA CI_END="23.086457116690056" CI_START="-2.6864571166900557" EFFECT_SIZE="10.2" ESTIMABLE="YES" MEAN_1="11.6" MEAN_2="1.4" ORDER="25388" SD_1="12.2" SD_2="12.4" SE="6.5748438330177414" STUDY_ID="STD-Burns-2006" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.0" CI_END="16.17588248104416" CI_START="-19.17588248104416" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="MD" EFFECT_SIZE="-1.5" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-003.06" NO="6" P_CHI2="1.0" P_Q="1.0" P_Z="0.8679009782387195" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="7" TOTAL_2="7" UNITS="" WEIGHT="100.0" Z="0.16632527286617327">
<NAME>Social functioning</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours control</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours sham insole</GRAPH_LABEL_2>
<CONT_DATA CI_END="16.17588248104416" CI_START="-19.17588248104416" EFFECT_SIZE="-1.5" ESTIMABLE="YES" MEAN_1="5.4" MEAN_2="6.9" ORDER="25389" SD_1="20.2" SD_2="12.7" SE="9.018473104847468" STUDY_ID="STD-Burns-2006" TOTAL_1="7" TOTAL_2="7" WEIGHT="100.0"/>
</CONT_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES/>
<FEEDBACK/>
<APPENDICES MODIFIED="2008-04-27 17:03:21 +0100" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2008-04-27 17:02:43 +0100" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2008-04-27 17:01:56 +0100" MODIFIED_BY="[Empty name]">PubMed MEDLINE Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-04-27 17:02:43 +0100" MODIFIED_BY="[Empty name]">
<P>(randomized controlled trial [pt] OR controlled clinical trial [pt] OR randomized controlled trials [mh] OR random allocation [mh] OR double-blind method [mh] OR single-blind method [mh] OR clinical trial [pt] OR clinical trials [mh] OR ("clinical trial" [tw]) OR ((singl* [tw] OR doubl* [tw] OR trebl* [tw] OR tripl* [tw]) AND (mask* [tw] OR blind* [tw])) OR ( placebos [mh] OR placebo* [tw] OR random* [tw] OR research design [mh:noexp] OR comparative study [mh] OR evaluation studies [mh] OR follow-up studies [mh] OR prospective studies [mh] OR control* [tw] OR prospectiv* [tw] OR volunteer* [tw])) NOT (animals [mh] NOT human [mh])<BR/>
<BR/>AND ((charcot OR (heredit* AND neuropath*) OR (inherit* AND neuropath*) OR (peroneal and atroph*) OR (distal and atroph*)) OR (Charcot-Marie-Tooth Disease [mh] OR hereditary motor and sensory neuropathies [mh] OR muscular atrophy, spinal [mh]))</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2008-04-27 17:03:02 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2008-04-27 17:02:10 +0100" MODIFIED_BY="[Empty name]">Ovid EMBASE Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-04-27 17:03:02 +0100" MODIFIED_BY="[Empty name]">
<P>1. Randomized Controlled Trial/<BR/>2. Clinical Trial/<BR/>3. Multicenter Study/<BR/>4. Controlled Study/<BR/>5. Crossover Procedure/<BR/>6. Double Blind Procedure/<BR/>7. Single Blind Procedure/<BR/>8. exp RANDOMIZATION/<BR/>9. Major Clinical Study/<BR/>10. PLACEBO/<BR/>11. Meta Analysis/<BR/>12. phase 2 clinical trial/ or phase 3 clinical trial/ or phase 4 clinical trial/<BR/>13. (clin$ adj25 trial$).tw.<BR/>14. ((singl$ or doubl$ or tripl$ or trebl$) adj25 (blind$ or mask$)).tw.<BR/>15. placebo$.tw.<BR/>16. random$.tw.<BR/>17. control$.tw.<BR/>18. (meta?analys$ or systematic review$).tw.<BR/>19. (cross?over or factorial or sham? or dummy).tw.<BR/>20. ABAB design$.tw.<BR/>21. or/1-20<BR/>22. human/<BR/>23. nonhuman/<BR/>24. 22 or 23<BR/>25. 21 not 24<BR/>26. 21 and 22<BR/>27. 25 or 26<BR/>28. Hereditary Motor Sensory Neuropathy/<BR/>29. Charcot Marie Tooth.mp.<BR/>30. (charcot or (heredit$ and neuropath$)).mp. [mp=title, abstract, subject headings, heading word, drug trade name, original title, device manufacturer, drug manufacturer name]<BR/>31. or/28-30<BR/>32. 27 and 31</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2008-04-27 17:03:21 +0100" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2008-04-27 17:02:23 +0100" MODIFIED_BY="[Empty name]">LILACS Search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2008-04-27 17:03:21 +0100" MODIFIED_BY="[Empty name]">
<P>((Pt RANDOMIZED CONTROLLED TRIAL OR Pt CONTROLLED CLINICAL TRIAL OR Mh RANDOMIZED CONTROLLED TRIALS OR Mh RANDOM ALLOCATION OR Mh DOUBLE-BLIND METHOD OR Mh SINGLE-BLIND METHOD) AND NOT (Ct ANIMALS AND NOT (Ct HUMAN AND Ct ANIMALS)) OR (Pt CLINICAL TRIAL OR Ex E05.318.760.535$) OR (Tw clin$ AND (Tw trial$ OR Tw ensa$ OR Tw estud$ OR Tw experim$ OR Tw investiga$)) OR ((Tw singl$ OR Tw simple$ OR Tw doubl$ OR Tw doble$ OR Tw duplo$ OR Tw trebl$ OR Tw trip$) AND (Tw blind$ OR Tw cego$ OR Tw ciego$ OR Tw mask$ OR Tw mascar$)) OR Mh PLACEBOS OR Tw placebo$ OR (Tw random$ OR Tw randon$ OR Tw casual$ OR Tw acaso$ OR Tw azar OR Tw aleator$) OR Mh RESEARCH DESIGN) AND NOT (Ct ANIMALS AND NOT (Ct HUMAN AND Ct ANIMALS)) OR (Ct COMPARATIVE STUDY OR Ex E05.337$ OR Mh FOLLOW-UP STUDIES OR Mh PROSPECTIVE STUDIES OR Tw control$ OR Tw prospectiv$ OR Tw volunt$ OR Tw volunteer$) AND NOT (Ct ANIMALS AND NOT (Ct HUMAN AND Ct ANIMALS))) AND NOT Mh ANIMALS [Words]<BR/>
<BR/>AND (charcot OR (heredit$ AND neuropath$) OR (inherit$ AND neuropath$) OR (peroneal AND atroph$) OR (distal AND atroph$)) [Words]</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>